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Human-based modelling and simulations are becoming ubiquitous in
biomedical science due to their ability to augment experimental and clinical
investigations. Cardiac electrophysiology is one of the most advanced areas, with
cardiac modelling and simulation being considered for virtual testing of
pharmacological therapies and medical devices. Current models present
inconsistencies with experimental data, which limit further progress. In this
study, we present the design, development, calibration and independent
validation of a human-based ventricular model (ToR-ORd) for simulations of
electrophysiology and excitation-contraction coupling, from ionic to whole-
organ dynamics, including the electrocardiogram. Validation based on
substantial multiscale simulations supports the credibility of the ToR-ORd model
under healthy and key disease conditions, as well as drug blockade. In addition,
the process uncovers new theoretical insights into the biophysical properties of
the L-type calcium current, which are critical for sodium and calcium dynamics.
These insights enable the reformulation of L-type calcium current, as well as
replacement of the hERG current model.
Decades of intensive experimental and clinical research have revealed much
about how the human heart works. Though incomplete, this knowledge has been
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used to construct computer models that represent the activity of this organ as a
whole, and of its individual chambers (the atria and ventricles), tissues and cells.
Such models have been used to better understand life-threatening irregular
heartbeats; they are also beginning to be used to guide decisions about the
treatment of patients and the development of new drugs by the pharmaceutical
industry.
Yet existing computer models of the electrical activity of the human heart are
sometimes inconsistent with experimental data. This problem led Tomek et al. to
try to create a new model that was consistent with established biophysical
knowledge and experimental data for a wide range of conditions including
disease and drug action.
Tomek et al. designed a strategy that explicitly separated the construction and
validation of a model that could recreate the electrical activity of the ventricles
in a human heart. This model was able to integrate and explain a wide range of
properties of both healthy and diseased hearts, including their response to
different drugs. The development of the model also uncovered and resolved
theoretical inconsistencies that have been present in almost all models of the
heart from the last 25 years. Tomek et al. hope that their new human heart
model will enable more basic, translational and clinical research into a range of
heart diseases and accelerate the development of new therapies.
Human-based computer modelling and simulation are a fundamental asset of
biomedical research. They augment experimental and clinical research through
enabling detailed mechanistic and systematic investigations. Owing to a large
body of research across biomedicine, their credibility has expanded beyond
academia, with vigorous activity also in regulatory and industrial settings. Thus,
human in silico clinical trials are now becoming a central paradigm, for
example, in the development of medical therapies (Pappalardo et al., 2018). They
exploit mature human-based modelling and simulation technology to perform
virtual testing of pharmacological therapies or devices.
Human cardiac electrophysiology is one of the most advanced areas in
physiological modelling and simulation. Current human models of cardiac
electrophysiology include detailed information on the ionic processes
underlying the action potential such as the sodium, potassium and calcium ionic
currents, exchangers such as the Na/Ca exchanger and pumps such as the Na/K
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pump. They also include representation of the excitation-contraction coupling
system in the sarcoplasmic reticulum, an important modulator of the calcium
transient, through the calcium-induced calcium-release mechanisms and the
SERCA pump. Several human models have been proposed for ventricular
electrophysiology, and amongst them the ORd model (O'Hara et al., 2011). Its key
strengths are the representation of CaMKII signalling, capability to manifest
arrhythmia precursors such as alternans and early afterdepolarisation, and
good response to simulated drug block and disease remodelling (Dutta et al.,
2016; Dutta et al., 2017a; Passini et al., 2016; Tomek et al., 2017). Consequently,
ORd was selected by a panel of experts as the model best suited for regulatory
purposes (Dutta et al., 2017a).
Most of the ORd model development has focused on repolarisation properties
such as its response to drug block, repolarisation abnormalities and its rate
dependence. However, a more holistic comparison of ORd-based simulations
with human ventricular experimental data reveals important inconsistencies.
Firstly, the plateau of the action potential (AP) is significantly higher in the ORd
model than in experimental data used for ORd model construction (O'Hara et al.,
2011; Britton et al., 2017) and in data from additional studies using human
cardiomyocytes (Coppini et al., 2013; Jost et al., 2013). Secondly, the dynamics of
accommodation of the AP duration (APD) to heart rate acceleration, which are
known to be modulated by sodium dynamics, show only limited agreement with
a comparable experimental dataset (Franz et al., 1988; O'Hara et al., 2011).
Thirdly, we identify that simulations of the sodium current block has an
inotropic effect in the ORd model, increasing the amplitude of the calcium
transient, in disagreement with its established negatively inotropic effect in
experimental/clinical data (encainide, flecainide, and TTX) (Gottlieb et al., 1990;
Tucker et al., 1982; Legrand et al., 1983; Bhattacharyya and Vassalle, 1982). All
those properties, namely AP plateau potential, APD adaptation and response to
sodium current block, have strong dependencies on sodium and calcium
dynamics. We therefore hypothesise that ionic balances during repolarisation
require further research. We specifically focus on an in-depth re-evaluation of
the L-type calcium current (I ) formulation, given its fundamental role in
determining the AP, the calcium transient and sodium homeostasis through the
Na/Ca exchanger. The second main focus is the re-assessment of the rapid
delayed rectifier current (I ), the dominant repolarisation current in human
ventricle, under conditions that reflect experimental data-driven plateau
potentials.
Using a development strategy based on strictly separated model calibration and
validation, we sought to design, develop, calibrate and validate a novel model of
human ventricular electrophysiology and excitation contraction coupling, the
ToR-ORd model (for Tomek, Rodriguez – following ORd). Our aim for simulations
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using the ToR-ORd model is to be able to reproduce all key depolarisation,
repolarisation and calcium dynamics properties in healthy ventricular
cardiomyocytes, under drug block, and in key diseased conditions such as
hyperkalemia (central to acute myocardial ischemia), and hypertrophic
cardiomyopathy.
Table 1 lists the properties (left column) and key references (right column) of
experimental and clinical datasets considered for the calibration (top) and
independent validation (bottom) of the ToR-ORd model. This represents a
comprehensive list of properties, known to characterize human ventricular
electrophysiology under multiple stimulation rates, and also drug action and
disease. The recordings in were obtained in human ventricular preparations
primarily using measurements with microelectrode recordings, unipolar
electrograms, and monophasic APs, therefore avoiding photon scattering effects
or potential dye artefacts present in optical mapping experiments. In addition,
the ToR-ORd model was calibrated to manifest depolarisation of resting
membrane potential in response to an I  block, based on evidence in a range of
studies summarised in Dhamoon and Jalife (2005). The calibration criteria are
chosen to be fundamental properties of ionic currents, action potential and
single-cell pro-arrhythmic phenomena (described in more detail in Appendix 1-
1). The validation criteria include response to rate changes, drug action and
disease, to explore the predictive power of the model under clinically-relevant
conditions.
Table 1
Criteria and human-based studies used in ToR-ORd calibration and validation.
Materials and methods
Strategy for construction, calibration and validation of
the ToR-ORd model
Request a detailed protocol
K1
Calibration
Action potential morphology (Britton et al., 2017; Coppini et al., 2013; Jost et al., 2013)
Calcium transient time to peak,
duration, and amplitude
(Coppini et al., 2013)
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We initially performed the evaluation of the ORd model (O'Hara et al., 2011) by
conducting simulations for each of the calibration criteria in Table 1. Further
details are described throughout the Materials and methods section and
Appendix 1-15.1. Simulations with the existing versions of the ORd model failed
to fulfil key criteria such as AP morphology, calcium transient duration, several
properties of the L-type calcium current, negative inotropic effect of sodium
blockers, or the depolarising effect of I  block. The results are later
demonstrated in Figures 2 and 3, and Methods: Calibration of I  block and
resting membrane potential. Secondly, we attempted parameter optimisation
using a multiobjective genetic algorithm (Torres et al., 2012). However,
simulations with the ORd-based models were unable to fulfil key criteria such as
AP and Ca morphology, and the effect of sodium and calcium block on calcium
transient amplitude and APD, respectively.
Calibration
I-V relationship and steady-state
inactivation of L-type calcium current
(Magyar et al., 2000)
Sodium blockade is negatively inotropic (Gottlieb et al., 1990; Tucker et al., 1982; Legrand et al.,
1983; Bhattacharyya and Vassalle, 1982).
L-type calcium current blockade
shortens the action potential
(O'Hara et al., 2011)
Early depolarisation formation under
hERG block
(Guo et al., 2011)
Alternans formation at rapid pacing (Koller et al., 2005)
Conduction velocity of ca. 65 m/s (Taggart et al., 2000)
Validation
Action potential accommodation (Franz et al., 1988)
S1-S2 restitution (O'Hara et al., 2011)
Drug blocks and action potential
duration
(Dutta et al., 2017a; O'Hara et al., 2011)
Hyperkalemia promotes
postrepolarisation refractoriness
(Coronel et al., 2012)
Hypertrophic cardiomyopathy
phenotype
(Coppini et al., 2013)
Drug safety prediction using
populations of models
(Passini et al., 2017)
Physiological QRS and QT intervals in
ECG
(Engblom et al., 2005; van Oosterom et al., 2000;
Bousseljot et al., 1995; Goldberger et al., 2000)
K1
K1
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We then proceeded to reevaluate the ionic current formulations based on
experimental data and biophysical knowledge. Key currents included I  and
specifically its driving force and activation, as well as the I , I , I  and
chloride currents. The multiobjective genetic algorithm optimisation was
repeated several times, throughout the introduction of structural changes to the
model. Once simulations with an optimised model fulfilled all calibration
criteria, validation was conducted through evaluation against additional
experimental recordings for drug block, disease, tissue and whole-ventricular
simulations.
Details concerning the simulations are given in Appendix 1-15.1, namely the
description of simulation protocols and ionic concentrations used (Appendix 1-
15.1.1), representation of heart disease (Appendix 1-15.1.2), 1D fibre simulations
(Appendix 1-15.1.3), population-of-models and drug safety assessment (Appendix
1-15.1.4), transmurality and whole-heart simulations with ECG extraction
(Appendix 1-15.1.5), and a technical note on the update to the Matlab ODE solver
which facilitates efficient simulation of the multiobjective GA (Appendix 1-
15.1.6). Unless specified otherwise, the baseline ORd model (O'Hara et al., 2011)
was used for comparison with the ToR-ORd model.
The ToR-ORd model follows the general ORd structure (Figure 1A). The
cardiomyocyte is subdivided into several compartments: main cytosolic space,
junctional subspace, and the sarcoplasmic reticulum (SR, further subdivided
into junctional and network SR). Within these compartments are placed ionic
currents and fluxes described by Hodgkin-Huxley equations or Markov models.
The main ionic current formulations altered compared to ORd are highlighted in
orange in Figure 1A.
Figure 1
CaL
Na Kr K1
ToR-ORd model structure
Request a detailed protocol
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Model structure.
(A) A schematic of the novel human ventricular myocyte model for electrophysiology and
calcium handling. Orange indicates components, substituted, or added, compared to the
original ORd model. ‘SS’ … see more »
The I  current was deeply revisited, particularly with respect to its driving
force, based on biophysical principles. This reformulation is of relevance to
almost all models of cardiac electrophysiology.
The I  formulation in the ORd model is based on Hodgkin-Huxley equations,
with the total current being a product of three components: 1) Open channel
permeability, 2) A set of gating variables determining the fraction of channels
being open, 3) The electrochemical driving force which acts on ions to move
through the open channel based on the membrane potential and ionic
In-depth revision of the L-type calcium current
CaL
CaL
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concentrations on both sides of the membrane (more details in Appendix 1-5). In
most Hodgkin-Huxley models of cardia currents, the driving force is computed
as (V-E ), that is, the membrane potential minus equilibrium potential, either
computed from the Nernst equation, or measured experimentally. However,
starting with the Luo-Rudy model (LRd) of 1994 (Luo and Rudy, 1994), the
driving force of ions via I  in cardiac models is modelled based on the
Goldman-Hodgkin-Katz (GHK) flux equation. The driving force based on the GHK
equation is:
where z is the charge of the given ion, V is the membrane potential, F,R,T are
conventional thermodynamic constants, and [S] , [S]  are intracellular and
extracellular activities of the given ionic specie. , where  is the ionic
activity coefficient and  the concentration (in either the intracellular or
extracellular space, yielding  or ).
In order to compute the ionic driving force via the GHK equation, it is necessary
to know the ionic activity coefficients of the intracellular (γ ) and extracellular
(γ ) space. The Luo-Rudy model and other Rudy-family models use γ  = 0.341 for
extracellular space and γ  = 1 for the intracellular space. Models based on the
Shannon model (Shannon et al., 2004) use 0.341 for both intracellular and
extracellular space, but we were unable to find the motivation for this change.
The Debye-Hückel theory is commonly used to compute the activity coefficients.
We used the Davies equation, which extends the basic Debye-Hückel equation to
be accurate for ionic concentrations found in living cells (Mortimer, 2008):
where A is a constant (~0.5 for water at 25°C, ~0.5238 at 37°C), z  is the charge of
the respective ion, and I is the ionic strength of the solution. The ionic strength is
defined as:
where m  is the concentration of the i-th ionic specie present. For concentrations
in a study measuring properties of I  (Magyar et al., 2000), I is ca. 0.15-0.17.
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This warrants the use of Davies equation, which was shown to be accurate for I
up to 0.5, unlike the basic Debye-Hückel equation, which is accurate for I up to
0.01 only (Mortimer, 2008).
We implemented the computation of ionic coefficients based on the Davies
equation dynamically, so that the activity coefficients are estimated at every
simulation step. This allows accurate representation of the driving force when
ionic concentrations are disturbed, such as at varying pacing rates, or during
homeostatic imbalance. The dynamic computation is also used to estimate ionic
activity coefficients for potassium and sodium flowing through the calcium
channels, taking into account their different charge.
Throughout our simulations, both intracellular and extracellular activity
coefficients generally lie between 0.61 and 0.66. Importantly, this estimate shows
that the intracellular and extracellular activity coefficients are relatively similar
(corresponding to the broadly similar total concentration of charged molecules),
in contrast with the original values. Particularly, the origin of the intracellular
activity coefficient γ  = 1 in the Luo-Rudy model is unclear, as by the Davies (or
by any Debye-Hückel variant) equation, I would have to be zero, which is
possible only when there are no ions present.
An additional improvement in the I  formulation is the estimation of its
activation curve. In brief, we implement a consistent use of the GHK equation
for the extraction of the activation curve and for the I  formulation in the ToR-
ORd model. The activation curve is obtained via dividing the
experimentally measured I-V relationship of the current by the expected driving
force for each pulse potential (see Appendix 1-3 for a graphical overview of the
process). However, we identified a theoretical inconsistency in previous cardiac
models across species (e.g. Luo and Rudy, 1994; Hund et al., 2008; O'Hara et al.,
2011; Shannon et al., 2004; Grandi et al., 2010; Carro et al., 2011): whereas the
Nernstian driving force of (V-E ) is used to derive the activation curve, the GHK
driving force is then used to calculate I . Indeed, experimental studies
reporting the activation curve of I  generally use the Nernstian driving force of
(V-E ) with E  being the experimentally measured reversal potential of
approximately 60 mV. This is explicitly stated in Linz and Meyer (2000), and also
the activation curve by Magyar et al. (2000) used in the ORd model is consistent
with dividing the IV relationship with (V-60).
In this study, we propose that, for consistency, the same equation needs to be
applied both to obtain the activation curve from the I-V curve and to represent
i
Activation curve extraction
Request a detailed protocol
CaL
CaL
Ca
CaL
CaL
Ca Ca
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the driving force in the current formulation. Thus, in the ToR-ORd model, the
activation curve for I  was obtained by dividing the I-V curve from Magyar et
al. (2000) by the GHK-based driving force, computed using ionic activity
coefficients based on the Davies equation (as explained in the previous Section)
and intracellular and extracellular ionic concentrations as in Magyar et al.
(2000). The following capped Gompertz function (a flexible sigmoid) was found
to be the best fit to the resulting steady-state activation curve:
where V is the membrane potential.
20% of I  was placed in the main cytosolic space, consistent with the literature
(Scriven et al., 2010). This increases the plateau-supporting capability of I ,
given that the myoplasmic I  is subject to a weaker calcium-dependent
inactivation than I  in the junctional subspace. Other minor changes are given
in Appendix 1-15.3.3.
The calibration of the ToR-ORd model’s AP morphology to experimental data
resulted in problematic response to calcium blockade during an early phase of
the model development when the original I  formulation was used (further
details in Appendix 1-12). I  block is known to shorten APD experimentally
(O'Hara et al., 2011) but resulted in a major APD prolongation in simulations
instead. This discrepancy could not be resolved through parameter optimisation.
A mechanistic analysis revealed that this follows from the lack of ORd I
activation, which is however not consistent with relevant experimental data (Lu
et al., 2001). We therefore considered alternative I  formulations and
specifically the Lu-Vandenberg (Lu et al., 2001) Markov model (Figure 1B). The
Lu-Vandenberg I  model is based on extensive experimental data allowing the
dissection of activation and recovery from inactivation and provided the best
agreement with experimental data, specifically when considering the AP plateau
potentials reported experimentally. In Appendix 1-12, we: (1) provide a detailed
explanation of origins of AP prolongation following I  block in a model which
manifests experimental data-like plateau potentials and which contains the ORd
I  formulation; (2) explain why this phenomenon occurs only in a model with
experimental data-like plateau potentials, but not in the original high-plateau
CaL
= (1.0763 ∙ forV ≤ 31.4978 1otherwise),d
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e
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ORd model; (3) compare the ORd and Lu-Vandenberg I  formulations with
experimental data, demonstrating the good agreement with experimental data
of the Lu-Vandenberg formulation but not the ORd.
Following the inclusion of the Lu-Vandenberg I  formulation, all models
generated during model calibration exhibited APD shortening in response to I
block.
The I  current formulation was replaced by an alternative human-based
formulation (Grandi et al., 2010), given established limitations of the original
model with regards to conduction velocity and excitability (O'Hara et al., 2011),
comment on article from 05 Oct 2012). The Grandi I  model was updated to
account for CaMKII phosphorylation (Appendix 1-15.3.1).
Also from the Grandi model, we added the calcium-sensitive chloride current
I  and background chloride current I  formulation (Grandi et al., 2010).
Neither model was changed compared to the original formulations, but the
intracellular concentration of Cl  was slightly increased (Appendix 1-15.1.1). In
accordance with recent observations, I  was placed in the junctional
subspace (Magyar et al., 2017). The motivation to add these currents was to
facilitate the shaping of post-peak AP morphology (via I ), with I  playing a
dual role stemming from its reversal potential of ca. −50 mV. It slightly reduces
plateau potentials during the action potential, but during the diastole, it
depolarises the cell slightly, improving the reaction to I  block as explained in
the next subsection.
The I  model was replaced with the human-based formulation by Carro et al.
(2011), as it was shown to be key for simulations of hyperkalemic conditions.
The I  replacement was done before hyperkalemia simulation, not violating the
classification of hyperkalemia criterion as a validation step. Extracellular
potassium concentration in a healthy cell was reduced from 5.4 to 5 mM to fall
within the physiological range (Zacchia et al., 2016).
When evaluating the baseline ORd model against the selected criteria, we
observed that a reduction in I  results in hyperpolarisation of the cell (from −88
to −88.16 mV at 1 Hz pacing). However, it is established that I  reduction
Kr
Kr
CaL
Changes in I  I  I  and I
Request a detailed protocol
Na, (Ca)Cl, Clb K1
Na
Na
(Ca)Cl Clb
-
(Ca)Cl
(Ca)Cl Clb
K1
K1
K1
Calibration of I  block and resting membrane potential
Request a detailed protocol
K1
K1
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depolarises cells experimentally (Dhamoon and Jalife, 2005). Changes made
during ToR-ORd calibration (predominantly the altered balance of currents
during diastole and the inclusion of background chloride current) result in ToR-
ORd manifesting depolarization in response to I  block, consistent with
experimental data.
We applied a multiobjective genetic algorithm (MGA, @gamultiobj function in
Matlab, Deb, 2001) to automatically re-fit various model parameters. Based on
preliminary experimentation, we used a two-dimensional fitness. We used MGA
rather than an ordinary genetic algorithm or particle swarm optimisation, given
that MGA optimises towards a Pareto front rather than a single optimum,
implicitly maintaining population diversity. The Pareto front is the set of all
creatures which are not dominated by any other creature in the population,
that is creatures for which there is no other creature better in all fitness
dimensions. Therefore, a subpopulation of diverse solutions is maintained, and
the optimiser consequently has less of a tendency to converge to a single local
optimum compared to single-number fitness approaches. In addition, the
crossover operator of GA is well suited for a task where multiple criteria are
optimised, given that creatures in the population may efficiently share partial
solutions to various subcriteria. The fitness used in this study is described in
greater detail in Appendix 1-1.
To facilitate the model validation and future work, we also provide an
automated ‘single-click’ evaluation pipeline. It runs automatic simulations to
extract and visualise single-cell biomarkers including those related to AP
morphology, effect of key channel blockers, early afterdepolarisations (EAD),
and alternans measurement. The pipeline generates a single HTML report
containing all the results; see Appendix 1-15.2 for a visualisation. The code for
our model (Matlab and CellML), the validation pipeline, and the experimental
data on human AP morphology are available at
https://github.com/jtmff/torord (Tomek, 2019; copy archived at
https://github.com/elifesciences-publications/torord). An informal blog giving
further insight into the choices we made, as well as general thoughts on the
development of ToR-ORd and computer models in general, is available at
https://underlid.blogspot.com/.
K1
Multiobjective genetic algorithm
Request a detailed protocol
Evaluation pipeline and code
Request a detailed protocol
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We designed the Matlab code used to simulate our model so that the simulation
core is structured into functions computing currents, making the high-level
organisation of code clear, and facilitating inclusion of alternative current
formulations. In addition, a CellML file encoding our model is also provided.
This makes the model readily runnable in several simulators in addition to
Matlab (e.g. Chaste [Pitt-Francis et al., 2009] and OpenCOR [Garny and Hunter,
2015]). Furthermore, the Myokit library (Clerx et al., 2016) enables conversion of
the CellML file to other languages (such as C or Python).
The AP morphology of the ToR-ORd is within or at the border of the interquartile
range of the Szeged-ORd experimental data (Figure 2A). This is a major
improvement compared to the original ORd morphology, which overestimates
plateau potentials, particularly during early plateau (Figure 2A). The fact that
the early plateau potential is around 20–23 mV is clearly apparent from
experimental recordings and is further corroborated by additional studies in
human tissue samples (Jost et al., 2013, Figure 6) and isolated human
cardiomyocytes (Coppini et al., 2013). We note that compared to the Szeged-ORd
dataset (Britton et al., 2017), our model manifests a slightly increased peak
membrane potential in the single-cell form, similar to single-cell experimental
data (Coppini et al., 2013). This is a design choice related to the fact that the
Szeged-ORd dataset contains recordings of small tissue samples, which are
expected to manifest a reduced peak potential compared to single-cell. When
coupled in a fibre, ToR-ORd manifests conduction velocity of 65 cm/s, which is
consistent with clinical data (Taggart et al., 2000).
Figure 2
Results
Calibration based on AP, calcium transient, and L-type
calcium current properties
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Action potential, calcium transient, and I  in ToR-ORd.
Action potential (A) and calcium transient (B) at 1 Hz obtained with the ToR-ORd model
following calibration, compared to those obtained with the ORd model and experimental
data from O'Hara et al. … see more »
Both time to peak calcium and duration of calcium transient at 90% recovery
obtained with the ToR-ORd model are within the standard deviation of
experimental data in isolated human myocytes (Coppini et al., 2013), whereas
ORd slightly overestimated the calcium transient duration (Figure 2B). The
calcium transient amplitude of ToR-ORd also matches the Coppini et al. data
after accounting for the different APD (Appendix 1-8).
As described in Materials and methods, the ToR-ORd I  activation curve was
extracted from experimental data, using the Goldman-Hodgkin-Katz formulation
of ionic driving force, ensuring theoretical consistency, unlike the ORd I
formulation (Figure 2C). This considerably improves the results of simulated
CaL
CaL
CaL
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protocols to obtain IV relationship (Figure 2D), validating the theory-driven
changes (see Appendix 1-4 for the demonstration of how the updated activation
curve underlies the improvement). The simulation of the protocol measuring
steady-state inactivation also reveals improved agreement of ToR-ORd with
experimental data compared to ORd (Figure 2E). The difference between
measured ORd steady state inactivation and the experimental data (ca. two
times stronger inactivation at around −15 mV, which is relevant for EAD
formation) is initially surprising, given that the equation of ORd I  steady-state
inactivation curve provides a good fit to the same experimental data. This
difference follows from the formulation of calcium-dependent inactivation of
I  (see Appendix 1-5 for details).
We observed that in cases of elevated I  (e.g. in midmyocardial cells), ORd
reverses current direction towards positive values, which is an unexpected
behaviour given its reversal potential of 60 mV. Conversely, the ToR-ORd model
yields negative I  values in such conditions, consistent with it being an inward
current (Figure 2F). This is a direct consequence of the updates to the
extracellular/intracellular calcium activity coefficients (as explained in
Appendix 1-6), which supports their credibility and it is important for cases of
elevated I , such as under ß-adrenergic stimulation.
We have also simulated a P2/P1 protocol as measured experimentally by Fülöp
et al. (2004), where two rectangular pulses are applied with varying interval
between them. Both ORd and ToR-ORd qualitatively agree with the experimental
data (Appendix 1-7).
Figure 3A-D illustrates AP and calcium transient changes caused by block of
sodium currents in ToR-ORd (left) and ORd (right). As sodium blockers act on
channel Na 1.5 mediating both the fast (I ) and late (I ) sodium current
(Makielski, 2016), we simulate the effect of combined partial I  and I  block.
The ToR-ORd model manifests a small reduction in calcium transient amplitude
(Figure 3C), unlike ORd, which gives a sizeable increase (Figure 3D); ToR-ORd is
thus consistent with the observed negative inotropy of sodium blockers (Gottlieb
et al., 1990; Tucker et al., 1982; Legrand et al., 1983; Bhattacharyya and Vassalle,
1982). This is a major improvement in the ToR-ORd model, as sodium current
reduction is involved in a range of disease conditions in addition to
pharmacological block.
Figure 3
CaL
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Calibration: inotropic effects of sodium blockers
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Sodium blockade in ToR-ORd and ORd.
Simulated effect of sodium current block on the action potential (A, B) and calcium
transient (C,D) using the ToR-ORd (left) and ORd (right) models. Control simulations are
shown as blue traces, … see more »
Experimental evidence shows that the ratio of I  and I  block is drug and
dose-dependent, with I  usually being blocked more than I  (Appendix 1-9).
Figure 3E,F illustrates the change in calcium transient amplitude obtained with
the ToR-ORd and ORd models, respectively, for several combinations of I  and
I  availability. Both models show a similar general trend where reduced I
availability increases calcium transient amplitude and reduced I  availability
diminishes it; however, the models differ strongly in relative contributions of
these components. The ToR-ORd model shows negative inotropy for almost all
combinations of blocks. A mild increase in inotropy may be achieved only under
near-exclusive I  block. Conversely, ORd shows a general tendency for
increased calcium transient amplitude; a reduction occurs only when the
Na NaL
NaL Na
Na
NaL Na
NaL
Na
This site uses cookies to deliver its services and analyse traffic. By using this site, you agree to its use of
cookies. Learn more.
GOT IT
2020. 09. 11. Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block | eLife
https://elifesciences.org/articles/48890#info 18/101
sodium current block targets near-exclusively I . ToR-ORd presents a greater
calcium transient amplitude reduction than ORd in response to I  block, as the
current has a greater role in indirect modulation the cell’s calcium loading via
APD change. At the same time, ToR-ORd shows a much smaller calcium transient
amplitude increase in response to I  block than ORd because of the updated
I  activation curve (Figure 2C), as well as closer-to experimental data AP
morphology (Figure 2A) and its effect on I . A detailed explanation is given in
Appendix 1-10.
Fibre simulations carried out to assess the effect of cell coupling on the effect of
sodium block are consistent with the single-cell simulations (Appendix 1-11). The
difference in response to half-block of I  and I  between ToR-ORd and ORd is
even larger, as ToR-ORd in fibre predicts a greater reduction in calcium transient
amplitude than in single cell (−14% vs −6% respectively), while ORd in fibre
predicts a slightly greater increase in calcium transient amplitude than in single
cell (+25% vs +24%).
With the ToR-ORd model, the 14% reduction in CaT amplitude in the
electrically coupled fibre with 50% block of both I  and I  is generally
consistent with clinical data on sodium blockers: Encainide reduced stroke work
index by 15% and cardiac index by 8% (Tucker et al., 1982). In another study
using encainide, the cardiac index was reduced by 18% and the stroke volume
index by 28% (Gottlieb et al., 1990). Flecainide reduced left ventricular stroke
index by 12% and the left ventricular ejection fraction by 9% (Legrand et al.,
1983). Simulations with the ToR-ORd model show overall agreement with the
clinical data. However, a direct quantitative comparison is challenging given the
different indices of contractility measured (CaT amplitude versus clinical
indices) and that it is not possible to estimate the exact ratios of I  and I
block in clinical data (Appendix 1-9).
EADs are an important precursor to arrhythmia, manifesting as a membrane
potential depolarisation during late plateau and/or early repolarisation. They
are thought to arise mainly from I  current reactivation (Weiss et al., 2010).
The ToR-ORd model manifests EADs at conditions used experimentally in
nondiseased human endocardium (Guo et al., 2011; Figure 4A). The amplitude of
simulated EADs is 14 mV (Figure 4B), which matches the maximum EAD
amplitude shown by Guo et al. (2011). We also note that the experimental data
by Guo et al. manifest early plateau potential of ca. 23 mV (which is matched by
ToR-ORd), in line with other studies we referred to previously regarding this
matter.
NaL
NaL
Na
CaL
CaL
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Na NaL
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Calibration: proarrhythmic behaviours (alternans and
early afterdepolarisations)
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Figure 4
EADs and alternans.
(A) Experimentally observed EADs produced in nondiseased human myocytes exposed to
0.1 µM dofetilide (∼85% I  block) paced at 0.25 Hz (Guo et al., 2011) and the
corresponding simulation using the … see more »
Repolarisation alternans is another established precursor to arrhythmia,
facilitating the formation of conduction block (Weiss et al., 2006). It is induced by
rapid pacing and it is mostly thought to arise from calcium transient amplitude
oscillations being translated to APD oscillations (Pruvot et al., 2004), although
purely voltage-driven mechanism was also proposed (Nolasco and Dahlen,
1968). Alternans in the ToR-ORd model is calcium-driven and appears via the
same mechanism as in the ORd: sarcoplasmic reticulum calcium cycling
refractoriness (Tomek et al., 2018). It occurs at rapid pacing, in both calcium and
APD (Figure 4C–F). The peak APD alternans amplitude (difference in APD
between consecutive beats) is 12 ms, which is matches the value 11 ± 2 ms
Kr
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reported in human hearts without a structural disease (Koller et al., 2005). Direct
quantitative comparison is however slightly limited by the fact that the data
were recorded in RV septum, which may or may not differ from endocardial
cells in alternans amplitude.
Figure 5 illustrates simulations of drug action using the ToR-ORd model (red
traces), compared to experimental data (black traces) and to simulations with
the ORd model reparametrised by Dutta et al. (2017a) (blue dashed lines). APD is
shown in the presence of I  block (E-4031, Figure 5A), I  block (HMR-1556
Figure 5B), multichannel block of I , I , I  (mexiletine, Figure 5C), and a I
block (nisoldipine, Figure 5D), at base cycle lengths of 500, 1000, and 2000 ms.
We note that while the Dutta et al. model was specifically optimised for response
of APD to these drug blocks, no such treatment was applied to the ToR-ORd
model, making the results presented here an independent validation. Appendix
1-13 contains further details on the choice and use of the drug data.
Figure 5
Validation: drug-induced effects on rate dependence of
APD
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Drug block and APD.
All four panels contain mean and standard deviation of experimental data (black) as
measured in O'Hara et al. (2011) for three basic cycle lengths (bcl), predictions of the
Dutta optimised dynamic-I  see more »
The predictions produced by the ToR-ORd model are in good agreement with
experimental data, particularly given the lack of optimisation towards this
result. Simulating E-4031, ToR-ORd provides a prediction similar to the
experimental data mean and the Dutta model (Figure 5A). This is crucial, given
the key role of I  in the repolarisation reserve of human cardiomyocytes. The
response to I  blockade via HMR-1556 is even better in ToR-ORd than in the
Dutta model, which is also within standard deviation of the data, but carries a
clear trend towards AP prolongation (Figure 5B). When simulating the
multichannel blocker mexiletine, ToR-ORd prediction is within standard
deviation of the experimental data, with the Dutta model giving similar or
closer-to-mean predictions at 0.5 and 1 Hz (Figure 5C). The predicted effect of the
calcium blocker nisoldipine in the ToR-ORd model matches well the
experimental data mean (Figure 5D), even better than the Dutta model (also
within standard deviation). We note that the good performance of the simulated
nisoldipine effect critically relies on the I  replacement (Materials and methods
and Appendix 1-12).
Experimental measurements in human cardiomyocytes (Franz et al., 1988;
Bueno-Orovio et al., 2012) show how the APD shortens upon increase in pacing
frequency, and then prolongs again, as the pacing frequency returns to control
(Figure 6A, top). APD adaptation dynamics with changes in heart rate are
regulated by changes in sodium homeostasis (Pueyo et al., 2011), and their
manifestation in QT adaptation have been shown to be useful for arrhythmia
risk prediction (Pueyo et al., 2004). While simulations with the ORd model
capture the general trend of APD accommodation, there are differences
compared to the experimental data (Figure 6A). First, changes in pacing rate are
followed by slow-dynamics (~30 s) APD prolongation not present in the
experimental recordings. Second, the time constant of accommodation is
generally slow. Conversely, the ToR-ORd model reproduces the pattern of
accommodation well, where the change in APD soon after change in frequency
is relatively fast, and then gradually slows down (Figure 6B). This suggests that
the ionic balance in ToR-ORd is likely to have been improved compared to ORd.
Figure 6
K…
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Validation: APD accommodation and S1-S2 restitution
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APD accommodation and S1-S2 protocol.
(A) APD accommodation measured experimentally (Franz et al., 1988) and in simulation
of the ORd model (reproduced as allowed by the CC-BY licence from O'Hara et al., 2011).
(B) APD accommodation in … see more »
A second indicator of how a model responds to a change in pacing frequency is
the S1-S2 restitution protocol. The S1-S2 restitution curve obtained with the ToR-
ORd model is given in Figure (Figure 6C), showing a good agreement with the
experimental data (O'Hara et al., 2011).
Drug safety testing is one of the key applications of computer modelling which
has yielded highly promising results (Passini et al., 2017). To assess the suitability
of ToR-ORd for drug safety testing, we replicated the study by Passini et al.
(2017), which was carried out using populations of models based on the ORd
model. Two populations were created based on ToR-ORd similarly to the original
study, altering conductances of important currents within the ranges of 50–150%
and 0–200%. Models in both populations are stable under significant
perturbation of ionic conductances, which supports the robustness of the model
(Figure 7A).
Figure 7
Validation: populations of models and drug safety
prediction
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Populations of models and drug safety prediction.
(A) Percentile-based summary of AP and calcium transient traces for the two populations
of human ToR-ORd models (left side) and distribution of ionic current conductances
among models in the … see more »
Prediction of the risk of drug-induced Torsades de Pointes based on simulated
drug-induced repolarisation abnormalities using ToR-ORd population yielded
similar results to the original study, with predicted risk being correct for 54 out
of 62 compounds (87% accuracy). Compared to Passini et al. (2017), the
assessment of Mexiletine (a predominantly sodium blocker that is safe) was
improved from false positive to true negative. High-dose Mexiletine led to
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formation of many EADs in ORd, but not in ToR-ORd (Figure 7B), highlighting the
importance of the advances on sodium blockers presented in this work. At the
same time, Procainamide and Metrodinazole were misclassified as false
negatives compared to Passini et al. (2017). However, these drugs are
controversial, as Metrodinazole is considered non-torsadogenic by Lancaster
and Sobie (2016), and this study predicted both the drugs to be non-risky.
Torsadogenic risk for all evaluated compounds and the confusion matrix of the
classification are given in Figure 7C.
Hyperkalemia, the elevation of extracellular potassium, is a hallmark of acute
myocardial ischemia caused by the occlusion of coronary artery. It was shown
that hyperkalemia can significantly inhibit sodium channel excitability
following repolarisation, leading to the prolongation of postrepolarisation
refractoriness (Coronel et al., 2012). The dispersion of effective refractory
periods (ERPs) between normal and ischemic zones forms a substrate for the
initiation of re-entrant arrhythmia. In this new model, we tested the effect of
hyperkalemia on tissue excitability using 1D fibres. As shown in Figure 8A, the
elevation of extracellular potassium level led to an increase of the resting
membrane potential (RMP) and the decrease of AP upstroke amplitude. As a
result of weaker upstroke and more depolarised RMP, the APD shortened under
hyperkalemia; however, the ERPs were prolonged due to the stronger sodium
channel inactivation caused by the elevation of RMP (Figure 8B). Therefore, this
new model successfully reproduced the longer post-repolarization refractoriness
under hyperkalemia observed in experiments, and it can be used in the
simulations of re-entrant arrhythmia under acute ischemia. In this regard, it
presents an improvement over the original ORd model, which did not manifest
postrepolarisation refractoriness without further modifications (Dutta et al.,
2017b).
Figure 8
Validation: response to disease
Hyperkalemia
This site uses cookies to deliver its services and analyse traffic. By using this site, you agree to its use of
cookies. Learn more.
GOT IT
2020. 09. 11. Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block | eLife
https://elifesciences.org/articles/48890#info 25/101
Simulation of hypertrophic cardiomyopathy (HCM) and hyperkalemia.
(A) The effect of hyperkalemia on AP morphology; measured in the centre of a simulated
fibre. (B) APD90 and effective refractory period (ERP) at varying extracellular potassium
concentration. For … see more »
Hypertrophic cardiomyopathy (HCM) is among the most common
cardiomyopathies, manifesting as abnormal thickening of the cardiac muscle
without an obvious cause (Coppini et al., 2013). Beyond mechanical remodelling,
the disease predisposes the hearts to arrhythmia formation, increasing the
vulnerability to early afterdepolarisations. HCM induces complex multifactorial
remodelling of cell electrophysiology and calcium handling, making it a
challenging validation problem for a computer model. We applied the available
human experimental data on HCM remodelling (based predominantly on
Coppini et al., 2013) to our baseline model using an approach similar to Passini
et al. (2016), observing that the dominant features of the remodelling observed
by Coppini et al. are captured. The HCM variant of the computer model
corresponds to experimental data in the AP morphology, manifesting a
significantly higher plateau potential and an overall APD prolongation (Figure
8C). The calcium transient amplitude of the HCM model is slightly reduced, has
longer time to peak, and a noticeably longer duration at 90% recovery (Figure
8D), also consistent with the data by Coppini et al. (2013). Ultimately, the HCM
Hypertrophic cardiomyopathy
This te uses cookies to deliver its servic s and analyse traffic. By using this site, you agree to its use of
cookies. Learn more.
GOT IT
2020. 09. 11. Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block | eLife
https://elifesciences.org/articles/48890#info 26/101
 
variant of our model is more prone to the formation of EADs (Figure 8E), as was
shown experimentally (Coppini et al., 2013). This difference is in line with
postulated key role of I  and NCX in EAD formation (Luo and Rudy, 1994; Weiss
et al., 2010), both of which are markedly increased in HCM. Excessive
prolongation of APD due to a strong increase in late sodium current in HCM also
contributes to the EAD formation as well, as shown by Coppini et al. (2013).
We conducted 3D electrophysiological simulations using the ToR-ORd model,
representing the membrane kinetics of endocardial, epicardial and mid-
myocardial cells to investigate their ability to simulate the ECG (see Appendix 1-
15.1.5). Transmural and apex-to-base spatial heterogeneities as well as fibre
orientations based on the Streeter rule were incorporated into a human
ventricular anatomical model derived from cardiac magnetic resonance (Lyon et
al., 2018).
Figure 9A shows the resulting electrocardiogram computed based on virtual
electrodes positioned on a torso model shown in Figure 9B. The ECG manifests a
QRS duration of 80 ms (normal range 78 ± 8 ms), and a QT interval of 350 ms
(healthy:<430 ms); all of these quantitative measurements are in the range of
ECGs of healthy persons (Engblom et al., 2005; van Oosterom et al., 2000). ECG
morphology also showed normal features, such as R wave progression in the
precordial leads from V1 to V6, isoelectric ST segment, and upright T waves in
leads V2 to V6, with inverted T wave in aVR. Figure 9C shows the activation
sequence is in agreement with Durrer et al. (1970). The APD map shows longer
APD in the endocardium and the base, and shorter APDs in the epicardium and
the apex, respectively (Figure 9D).
Figure 9
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Validation: human whole-ventricular simulations - from
ionic currents to ECG
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Simulated and clinical 12-lead electrocardiogram.
(A) 12-lead ECGs at 1 Hz: simulation using the ToR-ORd model in an MRI-based human
torso-ventricular model (top) and a healthy patient ECG record (bottom,
https://physionet.org, PTB database, … see more »
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In this study, we present a new model of human ventricular electrophysiology
and excitation contraction coupling, which is able to replicate key features of
human ventricular depolarisation, repolarisation and calcium transient
dynamics. The ToR-ORd model was developed using a defined set of calibration
criteria and subsequently validated on features not considered during
calibration to demonstrate its predictive power. This article also unravels
several important theoretical findings with implications for computational
electrophysiology reaching beyond the ToR-ORd model and cardiac
electrophysiology: firstly, the reformulation of the L-type calcium current, which
is broadly relevant and generally applicable to human and other species, and
secondly, the mechanistically guided replacement of I . Discovering the
necessity to carry out these theoretical reformulations was enabled by the
comprehensive set of calibration criteria and the use of a genetic algorithm to
fulfil them. Finally, to enable reproducibility, we openly provide an automated
model evaluation pipeline, which provides a rapid assessment of a
comprehensive set of calibration or validation criteria.
The AP morphology of ToR-ORd is in agreement with the Szeged endocardial
myocyte dataset used to construct the state-of-the art ORd model (O'Hara et al.,
2011). The agreement is considerably better than that of ORd itself, which has
important implications for multiple aspects studied in this work. The calcium
transient also recapitulates key features of human myocyte measurements
(Coppini et al., 2013). The validation of ToR-ORd shows that the model responds
well to drug block with regards to APD (Dutta et al., 2017a). Good APD
accommodation (reaction to abrupt, but persisting changes in pacing frequency)
indicates a good balance between ionic currents (Franz et al., 1988; Pueyo et al.,
2010). Replication of arrhythmia precursors such as early afterdepolarisations
(Guo et al., 2011) and alternans (Koller et al., 2005) makes the model useful for
simulations and understanding of arrhythmogenesis. This is particularly
important in the context of heart disease, where ToR-ORd is shown to replicate
key features of hyperkalemia (Coronel et al., 2012) and hypertrophic
cardiomyopathy (Coppini et al., 2013). The model is also shown to be promising
in drug safety testing, and whole-heart simulations demonstrate physiological
conduction velocity (Taggart et al., 2000) and produce a plausible ECG signal.
Among the improved behaviours compared to the state-of-the-art ORd model
(O'Hara et al., 2011), the good response of the ToR-ORd model to sodium
blockade is particularly noteworthy. ToR-ORd predicts the negative inotropic
effect of sodium blockade, consistent with data (Gottlieb et al., 1990; Tucker et
al., 1982; Legrand et al., 1983; Bhattacharyya and Vassalle, 1982), unlike ORd,
Discussion
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which suggests a strong pro-inotropic effect. The improvement in ToR-ORd
follows from the relatively complex interplay of the theoretically driven
reformulation of the L-type calcium current and data-driven changes to the AP
morphology. This result is of great importance in the context of pharmacological
sodium blockers, but it also plays a crucial role in disease modelling, where both
fast (Pu and Boyden, 1997) and late (Coppini et al., 2013) sodium current are
altered.
An important feature of a model is its predictive power, and validation of a
model using data not employed in model calibration is a central aspect of model
credibility (Pathmanathan and Gray, 2018; Carusi et al., 2012). With this in mind,
we designed our study to first calibrate the developed model using a set of given
criteria, with subsequent validation of the model using separate data that were
not optimised for during development. The fact that ToR-ORd manifests a wide
range of behaviours consistent with experimental studies, even though it was
not optimised for these purposes, suggests its generality and a large degree of
credibility. To facilitate future model development, we also created an
automated ‘single-click’ pipeline, which evaluates a wide range of calibration
and validation criteria and creates a comprehensive HTML report. New follow-
up models can thus be immediately tested against criteria presented here,
making it clear which features of the model are improved and/or deteriorated
by any changes made.
The greatest theoretical contribution of this work is the theory-driven
reformulation of the L-type calcium current, namely the ionic activity
coefficients and activation curve extraction. Activation curve of the current in
previous cardiac models was based on the use of Nernst driving force in
experimental studies, but the models then used Goldman-Hodgkin-Katz driving
force to compute the current. This yields a theoretical inconsistency present in
existing influential models of guinea pig, rabbit, dog, or human, for example
(Luo and Rudy, 1994; Hund et al., 2008; O'Hara et al., 2011; Shannon et al., 2004;
Grandi et al., 2010; Carro et al., 2011). We propose and demonstrate that in order
to obtain consistent behaviour, the experimental I-V relationship measurements
are to be normalised using the Goldman-Hodgkin-Katz driving force instead.
Updated ionic activity coefficients and activation of the L-type calcium current
improve key features of the current observed in the study underlying the ORd L-
type calcium current model (Magyar et al., 2000), and strongly contribute to the
improved reaction of the model to sodium blockade. The changes made are
relevant in development of future models which use the Goldman-Hodgkin-Katz
equation for L-type calcium current or other currents.
A second major contribution of this work reaching beyond the model itself is the
set of observations on modelling of I , the dominant repolarising current inKr
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human ventricle. We noticed limitations of the ORd I  model, which may be a
result of the single-pulse voltage clamp protocol to characterise the current
behaviour. Approaches enabling the dissection of activation and recovery from
inactivation based on more comprehensive experimental data, such as Lu et al.
(2001) used in our work, may yield a more general and plausible model. In this
study, this change was important predominantly for the response of the
ventricular cell to calcium block, but our observations are highly relevant also
for models of cells with naturally low plateau, such as Purkinje fibres or atrial
myocytes.
We anticipate that the main future development of the presented model will
focus on the ryanodine receptor and the respective release from sarcoplasmic
reticulum. Similarly to most existing cardiac models, the equations governing
the release depend directly on the L-type calcium current, rather than on the
calcium concentration adjacent to the ryanodine receptors, which is the case in
cardiomyocytes. Future development of the ryanodine receptor model and
calcium handling will extend the applicability of the model to other calcium-
driven modes of arrhythmogenesis, such as delayed afterdepolarisations. Also,
while the model represents to a certain degree the locality of I  calcium influx
and calcium release via the utilization of the junctional calcium subspace, a
more direct representation of local control (Stern, 1992; Hinch et al., 2004),
realistic spatially distributed calcium handling (Colman et al., 2017), or
representation of stochasticity, may improve the insights the model can give into
calcium-driven arrhythmogenesis. However, we note that such changes
(particularly the detailed distributed calcium handling) will increase
computational cost of the model's simulation. In addition, further research on
the mechanisms regulating AP dependence on extracellular calcium
concentration is needed to update this feature, not currently reproduced by
most current human models (Passini and Severi, 2014).
This section provides additional information to the criteria listed in Table 1.
The AP morphology was based primarily on the large experimental dataset of
human undiseased endocardial recordings from the Varró lab, published in
Britton et al. (2017). The ORd model (O'Hara et al., 2011) was based on a subset of
these recordings. We aimed for similarity with the median of the AP data during
Kr
CaL
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the plateau and repolarization phase (from 15 ms after the AP peak). Two other
datasets were used to confirm that early plateau potentials are ca. 20 mV, rather
than the >30 mV as in ORd (Coppini et al., 2013; Jost et al., 2013).
The calcium transient morphology (CaT amplitude and duration at 90%
recovery) was based on Coppini et al. (2013), particularly given it is clear that the
AP morphology is similar in their experimental recordings and the simulations
with the TOR-ORd model. The aim was for the two CaT properties to lie within
standard deviation of mean. A correction for the difference in APD with regards
to CaT amplitude was made in Appendix 1-8.
The properties of I , the I-V relationship and steady-state inactivation were
taken as reported in Magyar et al. (2000), as this is the primary dataset used in
the ORd I  construction. Visual assessment of simulations versus data was
used.
Negative inotropy of sodium blockers was based on Gottlieb et al. (1990); Tucker
et al. (1982); Legrand et al. (1983); Bhattacharyya and Vassalle (1982), which
report 8–28% reduction in whole-heart contractility, depending on drug, dose
and index of contractility. Given the variability, throughout the calibration of a
single-cell model, we aimed for any reduction in CaT amplitude following 50%
reduction of I  and I .
The blockade of I  is known to shorten APD across species, including human
(O'Hara et al., 2011). Within the process of calibration, we aimed for any APD
shortening at 50% I  reduction.
EADs were shown to form under ca. 85% I  block in human myocytes at 0.25 Hz
pacing (Guo et al., 2011). Thus, we aimed for the new model to manifest EADs of
similar amplitude as in the data (ca. 14 mV) in corresponding conditions.
APD alternans was observed in undiseased human cells at rapid pacing (Koller
et al., 2005). We aimed for a model manifesting APD alternans, with the onset at
basic cycle length shorter than 300 ms.
The reported conduction velocity in human heart is 65 m/s (Taggart et al., 2000),
and we compared this value to the result of a fibre simulation using the
developed ToR-ORd model.
The fitness function has 18 inputs, 16 of which are the multipliers of
conductances for the following currents and fluxes: I , I , I , I , I , I , I ,
CaL
CaL
Na NaL
CaL
CaL
Kr
2. Genetic algorithm fitness
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I , I , I , I , I , I , I , J , J . Also varied were , a parameter
of J  (constrained between 0.9 and 1.7) and the fraction of I  in the
junctional subspace (constrained between 0.18 and 0.4).
If the genetic algorithm (GA) employed symmetric percentual variations of raw
current multipliers (e.g., + /- 50%), it would not sample the input space evenly –
for example, a symmetric Gaussian mutation is much more likely to halve a
parameter than to double it (assuming the Gaussian curve being centred at 1, the
density in 0.5 is the same as in 1.5, but not in 2), while the likelihood should be
arguably the same. The initial population would also likely be highly skewed
towards current reduction. In order to avoid these issues, we made the GA work
internally with logarithms of multipliers, which makes the sampling
symmetrical (-log(0.5)=log(2), etc.). The fitness function first exponentiates the
log-multipliers to obtain the actual multipliers, and these are subsequently used
in further simulation.
Within the fitness function, the evolved model is pre-paced for 130 beats at 1 Hz,
with the final state X . Subsequently, 20 more beats are simulated at the
following conditions, with X  as the starting state: a) no change to parameters,
b) sodium blockade (50% I  block, 50% I  block), c) calcium blockade (50%
I  block), d) I  blockade (50% block). 150 beats in total for the control
condition is a compromise between total runtime and similarity to the stable-
state behaviour. The 20 beats at various conditions following 130 beats of
prepacing are sufficient to manifest the effects of the respective blocks , while
keeping the runtime low (When the model is evaluated in the manuscript, the
outputs are based on 1000 beats of pre-pacing; the 150 or 130+20 beats are used
only during model refitting to allow sufficiently fast runtime.).
Based on these simulations, a two-element fitness vector is obtained; the first
element describes similarity of action potential (AP) morphology to the
reference, with the second element aggregating other criteria (calcium transient
duration and amplitude, calcium transient amplitude reduction with sodium
blockade, action potential duration (APD) reduction with calcium blockade, and
a depolarisation with I  block).
Not all calibration criteria (Table 1) were represented in the fitness function, as
simulating all corresponding protocols would be prohibitively slow. Instead, the
calibration criteria not optimized using the genetic algorithm were subsequently
fulfilled by mechanistically informed manual changes, while making sure the
already optimised criteria were not violated.
Kb NaCa NaK Nab Cab pCa CaCl rel up K∞ ,Rel
rel NaCa
130
130
Na NaL
CaL K1
K1
3. Extraction of I  activation from I-V relationshipCaL
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The experimental protocol to measure I-V relationship of the I  uses square
pulse stimuli to measure peak current for different pulse potentials (Appendix 1
—figure 1, top left). The peak current can be seen as the product of two
components: activation (how open the channels are) and driving force (the
strength of the diffusion and electrical gradients that produce ionic flow through
the open channels). To obtain the activation value for each pulse potential, the
corresponding peak current is divided by the theoretical estimate of the driving
force. The resulting curve can then be scaled to 0–1, producing estimated
fractional activation (Appendix 1—figure 1, top right). The driving force may be
computed based on the linear equation V-E , or the nonlinear Goldman-
Hodgkin-Katz (GHK) flux equation (Appendix 1—figure 1, bottom left and
bottom right, respectively). This yields the two corresponding activation curves
in Appendix 1—figure 1, top right.
Appendix 1—figure 1
Diagram of how activation curves are extracted from the I-V relationship.
The activation curves (top right) are obtained by dividing values in the I-V curve (top left)
at each pulse potential by the driving force considering either V-E -based driving force
(bottom right) … see more »
CaL
Ca
Ca
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Appendix 1—figure 1 can be also used to illustrate the theoretical inconsistency
in the ORd model and many other models (e.g. Luo and Rudy, 1994; Hund et al.,
2008; O'Hara et al., 2011; Shannon et al., 2004; Grandi et al., 2010; Carro et al.,
2011): the V-E  driving force is used to obtain the activation curve, but then the
I  is computed using the GHK driving force, which does not yield the original
data, as illustrated in the Results section. Returning to the notion of I-V
relationship as a product of activation and driving force, the same shape of I-V
relationship can be obtained by pointwise multiplication of the blue driving
force (bottom, left) with blue activation (top, right), or the red driving force
(bottom, right) with red activation (top, right). However, simulating the I-V
relationship using the ORd model corresponds to the product of blue activation
and the red driving force, which then naturally does not match greatly the
original I-V relationship (Figure 2D, or Appendix 1—figure 2 in Appendix 1-4).
Appendix 1—figure 2
Effect of the proposed changes in the activation curve and activation coefficient on
the I-V relationship of I  in ORd versus ToR-ORd.
Appendix 1—figure 2 illustrates the effect that updates in activation curve and
activation coefficients have on the simulated I  I-V relationship considering
four models:
Ca
CaL
CaL
4.I  updates and the I-V relationshipCaL
CaL
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Control ORd
ORd with updated activity coefficients as in ToR-ORd (fixed to 0.6532/0.6117
for intracellular/extracellular calcium, 0.89/0.88 for intracellular/extracellular
sodium; the same also for potassium)
ORd with updated activation curve as in ToR-ORd • ToR-ORd model.
The I-V curves were normalised to a minimum of −1, in order to focus on the
shape of the I-V curve rather than its amplitude (which is modulated by maximal
conductance). Considering the new activation curve extracted using the GHK
equation in the ORd model yields a near-identical I-V curve to the ToR-ORd
model (Appendix 1—figure 2). This demonstrates this is the key mechanism in
the I-V curve improvement. The update of activity coefficients did not alter the
shape of the I-V relationship noticeably compared to the ORd model (Appendix 1
—figure 2), but played a key role in avoiding the reversal of I  illustrated in
Figure 2F and a good response to sodium block, as explained in the next section.
As shown in Figure 2E of the main manuscript, the steady-state inactivation
curve of the ORd model differs from the experimental data. This is surprising,
given that both the steady state voltage and calcium inactivation in the model
are a direct fit to the experimental data. The explanation of this phenomenon
lies in the construction of the I  equation in the ORd model, which is as follows
(only the non-phosphorylated part is given; the phosphorylated is analogous):
where  is the product of driving force and channel conductance,  is
activation,  is voltage-driven inactivation,  is a weight of calcium inactivation, 
 is calcium-driven inactivation, and  corresponds to recovery from
inactivation. In the ORd model, stable-state values of  are all fit to the
steady-state inactivation in Magyar et al. (2000). During a long voltage clamp
pulse used to inactivate I ,  and  can be assumed to be constant, leaving
the remaining parentheses as the factor determining measured inactivation. If 
 was equal to 1, then the equation would reduce to the experimentally
observed inactivation in the steady state (however, this prevents formation of
EADs). However, given that  effectively acts as a second inactivation, the 
 product corresponds to a square of the experimentally observed
inactivation, making the inactivation stronger. Thus, for , this I  model
CaL
5. Extraction of steady-state inactivation of ICaL
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manifests total steady-state inactivation stronger than the one from Magyar et
al. (2000).
As shown in Figure 2E of the main manuscript, this problem is not present in the
ToR-ORd model, which yields a better match with experimental data than ORd.
Inspecting state variables at the inactivating pulse potentials where the models
differ (approximately between -30 and -5 mV), we observed that the ORd model
has a higher level of calcium in the subspace, increasing the value of the 
variable, making the contribution of the overestimated inactivation stronger.
The higher calcium level in the subspace in the ORd model seems to arise from a
combination of two factors: (1) Overestimated activation and thus enhanced
calcium entry in ORd (evident from Figure 2 C, D in the main manuscript),
accompanied by small differences in J  formulation translating into more SR
release in ORd; (2) less total NCX in the subspace, corresponding to less calcium
clearance.
It is worth noting that the exact shape of the simulation-based inactivation curve
depends on how exactly the conditions in Magyar et al. (2000) are represented.
As explained in Appendix 1-15.1.1, intracellular and potassium are fixed when
the steady-state inactivation is measured, but calcium is not fixed. If the
intracellular calcium in the model was also clamped to the zero concentration of
the pipette,  would be zero and both ORd and ToR-ORd would fit the
inactivation curve well.
As illustrated in Figure 2F, the ToR-ORd model yields a consistently inward I
during the AP, whereas for the ORd, there is a reversal to outward I  following
the peak of the AP. For the ORd midmyocardial cell, I  is highly positive
(I  = 3.32 pA/pF) at t = 4.3 ms. This can be explained by the update in the ionic
activity coefficients described in section Methods: Determining ionic activity
coefficients. The sign of I  is determined by the sign of the driving force (other
components of I  are the permeability constant, and gating variables, both of
which are nonnegative). The GHK equation for driving force (with all elements
explained in Materials and methods of the main manuscript) can be divided into
four components for clarity (Appendix 1—figure 3). Components 1 and 4 are
positive (V = 33 mV at this point of simulation) and thus do not affect the sign;
therefore, the sign of the driving force in this case is determined by the relative
size of components 2 and 3. In control ORd (with activity coefficients of 1 and
0.341 for intracellular/extracellular space), we have, for components C2 and C3:
n
rel
n
6. I  reversal and ionic activity coefficientsCaL
CaL
CaL
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where  are intra/extracellular activity coefficients,  is the calcium
concentration in junctional subspace, and  is extracellular calcium
concentration. Therefore, C2 > C3 and the sign of driving force (and thus also
I ) is positive.
Appendix 1—figure 3
Goldman-Hodgkin-Katz equation with colour coding of components.
However, if we use ionic activity coefficients based on ToR-ORd (0.6532 and
0.6117 for intracellular/extracellular), we get:
Therefore, in this case, C2 < C3, and the sign of driving force and I  is negative
and thus consistently inward during the AP.
We compared the results of the ToR-ORd and ORd models to experimental data
in human myocytes for the P2/P1 protocol reported by Fülöp et al. (2004) as
previously shown in the original ORd model study (O'Hara et al., 2011). In this
protocol, two rectangular pulses (from −40 mV to 10 mV, lasting either 25 ms or
100 ms) are applied, and the ratio of peak I  during the second pulse versus the
first one is computed. Simulated curves with both models are consistent with the
data in that a) 25 ms pulse curve lies above the 100 ms pulse curve, b) shorter
coupling interval is associated with less current availability (Appendix 1—figure
4). Both models show an offset to the experimental data. This could be due to a)
C3 = = ∙ = 0.341 ∙ 1.8 = 0.6138[S]
o
γ
o
m
o
γ
i
, γ
o
m
i
m
o
CaL
C2 = ∙ = 0.6532 ∙ 0.0822 ∙ 11.6794 = 0.6269γ
i
m
i
∙e
z∙V∙F
R∙T
C3 = ∙ = 0.6117 ∙ 1.8 = 1.1011γ
o
m
o
CaL
7. P2/P1 protocol for ICaL
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Difference in I  behaviour/density and/or calcium loading (affecting
inactivation) between the Fülöp (P2/P1 protocol) and Magyar (the main basis for
the I  model) studies. It could be also linked to mechanisms of I  inactivation
not represented in the model (e.g. the inactivation by the calcium flow through
the channel, represented for example by Mahajan et al., 2008).
Appendix 1—figure 4
P2/P1 protocol for two pulse durations.
The calcium transient amplitude of 312 nM in baseline ToR-ORd is slightly below
the mean ± std range of 350 (330-370) nM in Coppini et al. (2013). However, we
hypothesised that the difference might be due to the different APD, which affects
the calcium loading of the cell by modulating I  duration. When the APD of the
ToR-ORd was extended to 351.5 ms (close to ca. 350 ms reported by Coppini et al.)
by reducing I  by 45%, the calcium transient amplitude increased to 360 nM,
which is close to the data mean. After such an AP prolongation, both time to
peak (54 ms) and calcium transient duration at 90% recovery (459 ms) remained
within standard deviation of the data.
CaL
CaL CaL
8. Calcium transient amplitude in ToR-ORd
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The exact ratio of pharmacological block of I  and I  is drug and dose-
dependent, with late sodium current generally being blocked somewhat more
than the fast sodium current. For flecainide applied to wild-type Na 1.5, the IC50
value of I  and I  were 127 ± 6 and 44 ± 2 μM, respectively; for example, for
50% I  block, a 75% I  block would be expected (Nagatomo et al., 2000). In the
case of TTX, the IC50 values appear to be more similar for the two currents: 1.2
μM for I  (Bradley et al., 2013) and 0.95 μM for I  (Horvath et al., 2013).
Lidocaine also appears to block I  preferentially: the measured IC50 for I  is
10.79 μM (Crumb et al., 2016), which is lower than 44 μM measured for I
(Janssen Pharmaceutical internal database, referred to in Passini et al., 2017).
However, we note that comparing IC50 values between studies has limited
quantitative relevance, given expected differences between conditions and
protocols.
The changes in AP morphology and I  introduced in the ToR-ORd model
improved its response to Na currents block, particularly with respect to
reduction of the Ca transient amplitude (illustrated in Figure 3). To further
dissect the contribution of differences between ToR-ORd and ORd in AP
morphology and I  properties, we simulated two AP clamp scenarios using the
four different models considered previously in Appendix 1—figure 2 (i.e. ORd,
ORd and ToR-ORd activity coefficients, ORd and ToR-ORd I  activation curve,
and ToR-ORd). The first scenario applied an AP clamp based on ORd AP
morphologies for control and for 50/50% I /I  block (as shown in Figure 3B).
The second scenario considered AP clamps based on ToR-ORd AP morphologies
in control and 50/50% I /I  block (as shown in Figure 3A). For each of the four
models and the two AP clamp scenarios, the ratio of calcium transient
amplitudes (sodium-block versus control) was computed (Appendix 1—table 1).
This allowed quantifying the importance of differences in AP morphology and
updates to the I  representation with regard to CaT amplitude changes under
sodium block.
Appendix 1—table 1
Dissection of improvement in reaction to sodium blockade.
Ratios of calcium transient amplitudes for AP clamps corresponding to baseline and
sodium-blocked models, arising from ORd and ToR-ORd. Row/column numbering used
9. Summary of literature on sodium blockers, I , and
I  reduction
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NaL
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10. Role of I  properties and AP morphology in calcium
transient changes by sodium blockade
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in the text does not include the … see more »
A value below one in Appendix 1—table 1 indicates the expected decrease in
calcium transient amplitude with sodium block compared to control. This was
achieved only by using the ToR-ORd AP clamp with the ToR-ORd model (row 4,
column 2), and also but to a lesser extent with the ToR-ORd AP clamp and the
ORd with ToR-ORd activity coefficients (row 2, column 2). Considering the ToR-
ORd AP morphology (versus I  activation coefficients or activation curves) has
the strongest effect in changes in calcium transient amplitude with sodium
blockade. This is demonstrated by the universally lower values in the second
column of Appendix 1—table 1 compared to the first column. The update of ionic
activity coefficients alone leads to a reduced increase in CaT amplitude (in ORd),
or a reduction in CaT amplitude (in ToR-ORd) following sodium blockade
(Appendix 1—table 1, row 2 versus 1). Updated activation curve leads to a less
pronounced increase in calcium transient amplitude in both models (Appendix 1
—table 1, row 3 versus 1). Using the fully updated ToR-ORd model for
simulations gave the most pronounced reduction in how much the calcium
transient is increased upon sodium blockade using ORd AP clamps (Appendix 1
—table 1, row 4 versus 1; column 1). It also yielded the most pronounced
reduction in calcium transient amplitude following sodium blockade when using
ToR-ORd AP clamps (Appendix 1—table 1, row 4 versus 1; column 2).
AP morphology and peak AP levels regulate calcium transient amplitude
through I , and specifically through its voltage-dependency of activation curve,
driving force and inactivation. It is important to note key differences between
ToR-ORd and ORd models in this respect. In the ToR-ORd model, the AP
morphology and the I  activation curve (Figure 2C) mean that I  blockade
leads to a reduction of peak I  activation. Conversely, in ORd, the activation
curve is flat from 15 mV on (Figure 2C), and activation is not affected when
sodium block reduces peak and early-plateau potential from 40 mV to 30–35 mV.
At the same time, lowered peak and early-plateau potentials following sodium
blockade increase I  driving force and weaken the voltage-driven inactivation,
enhancing total I . Furthermore, in the ToR-ORd model, AP with and without
sodium block reach a near-identical notch and early-plateau potential soon after
the peak (Figure 3A). However, in the ORd, the difference in early-plateau
Model ORd AP clamps ToR-ORd AP clamps
M1 (ORd) 1.366 1.061
M2 (ORd with ToR-ORd activity coefficients) 1.301 0.999
M3 (ORd with ToR-ORd activation curve) 1.326 1.015
M4 (ToR-ORd) 1.193 0.985
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membrane potentials lasts almost 30 ms after the peak (Figure 3B), prolonging
the effect of increased driving force and reduced inactivation on I , which is
furthermore not compensated by reduction in activation.
To further explore the impact of AP morphology on I  properties, I
activation and driving force was computed with the ToR-ORd model, again
under four AP clamps considering AP morphologies shown in Figure 3A,B
(obtained with ToR-ORd control and 50/50% I /I L block, and ORd control and
50/50% I /I  block). The results are presented in Appendix 1—figure 5. The
activation with ToR-ORd AP clamp is reduced with sodium block versus control
AP clamp morphologies (Appendix 1—figure 5A, yellow vs purple), given the
difference in peak membrane potentials (Figure 3A) and their position on the
activation curve (Figure 2C). However, the activation over time is similar with
ORd AP morphology in control versus sodium block (Appendix 1—figure 5A, red
vs blue), as the membrane potential is so high that full activation is reached in
both cases.
Appendix 1—figure 5
Effect of AP morphology on I  variables under sodium blockade.
(A) I  activation. (B) ICaL driving force. In (C) are shown ratios of curves from (B) red
pointwise-divided by blue (shown in light blue) and purple pointwise-divided by yellow
(shown in green).
Furthermore, the I  driving force obtained with the four AP clamps is shown
in Appendix 1—figure 5B (more negative values correspond to a greater driving
force), and Appendix 1—figure 5C displays the ratio of the driving forces
between sodium-blocked AP clamp and control AP clamp for ORd and ToR-ORd
morphologies. It is clear that the driving force elevation under sodium-block AP
morphology versus control is much smaller and shorter lasting when clamping
to ToR-ORd than ORd AP morphologies (Appendix 1—figure 5C).
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Therefore, the combination of ToR-ORd AP morphology and I  activation curve
(which is consistent with experiments and with lower peak and early plateau
voltages compared to ORd) result in reduction in both activation and driving
force of I  with sodium bock. This explains how I  block causes a smaller
increase in I  and thus also in calcium transient amplitude using the ToR-ORd
versus ORd models (Figure 3E and F). This smaller calcium increase due to I
block is further compensated by the reduction in calcium entry and loading
caused by I  block. The effect of I  on the simulated cell’s calcium loading is
mediated by the NCX (reduced sodium influx via I  reduces calcium influx via
NCX) and by I  (APD shortening induced by I  reduction also shortens I ,
reducing calcium influx). Given that the effect of fixed-amount I  reduction on
APD is stronger in ToR-ORd compared to ORd (Figure 3A,B), I  loss reduces
calcium transient amplitude more in ToR-ORd.
In order to assess how cell coupling affects the sodium block behaviour, we
simulated half-blocks of I  and I  in fibre (Appendix 1—figure 6). The effect of
the respective blocks is generally consistent with single-cell behaviour (Figure 3)
in that I  block increases calcium transient amplitude, and I  block reduces it.
The effect of both half-blocks combined shows the same trend as the single-cell
but is of greater magnitude: ToR-ORd shows a greater reduction in the calcium
transient amplitude, while ORd shows a greater increase. In this section, a
version of ORd with updated I  to allow for good propagation was used (Passini
et al., 2016), and the tissue conductivity was set to achieve the conduction
velocity of 63 m/s.
Appendix 1—figure 6
CaL
CaL Na
CaL
Na
NaL NaL
NaL
CaL NaL CaL
NaL
NaL
11. Sodium block in fibre
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Effect of sodium blockers on ToR-ORd and ORd in fibre.
Membrane potential in fibre at four simulated conditions (control, half block of fast
sodium, half block of late sodium, and half block of both fast and late sodium currents)
in ToR-ORd (A) and ORd … see more »
During the model development (with the original ORd formulation of I  being
used at the stage), we observed that in models with good AP morphology and
response to sodium block, 50% I  block resulted in APD prolongation, which is
in conflict with experimental evidence. Dissecting the cause of this
phenomenon, we noticed considerably diminished I  density upon such
treatment. Given that I  is the dominant repolarising current in human
ventricle and human-specific computer models, this led to a net APD
prolongation. The diminished I  density is due to the lack of activation of I
following from the combination of data-like AP morphology and formulation of
fast and slow time constant of activation (Figure 3A in O'Hara et al., 2011). These
time constants indicate a rapid activation between 25 and 40 mV, but when the
membrane potential is reduced below 15 mV, activation time increases steeply
(both fast and slow time constant are >1000 ms at 0 mV). Therefore, when the
12. Calibration: I  block and I  replacementCaL Kr
Kr
CaL
Kr
Kr
Kr Kr
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50% I  block reduces plateau potential (a reduction of ca. 10 mV from control
data-driven values of ca. 20 mV at 10 ms, 10 mV at 100 ms), I  activation is
slowed greatly, producing a reduction in current density.
Subsequently, we sought to understand why this problem was not present in the
original ORd model, which was shown to respond well to I  block with regard
to APD (O'Hara et al., 2011; Dutta et al., 2017a). This follows from the high-
plateau AP configuration of ORd (ca. 38 mV at 10 ms and 20 mV at 100 ms); when
such a high plateau is lowered by 10 mV, it still falls within the zone of rapid I
activation. Under such conditions, the loss of I  shortens the APD much more
than the minor loss of I  prolongs it, with the net effect being APD shortening.
Importantly, the article describing the Lu-Vandenberg model of I  (Lu et al.,
2001) used in the final version of ToR- ORd also provides I  measurements
under AP clamp. The study utilises AP clamps of both normal-plateau
ventricular AP and low-plateau Purkinje AP (which can be taken as a proxy for
I  blocked ventricular cell). The experimentally measured peak I  is slightly
reduced in low-plateau AP clamp versus the high-plateau one (reduction to 70%).
This is generally captured by simulations using our version of the Lu-
Vandenberg model (reduction to 57%, Appendix 1—figure 7). However, peak I
in ORd reduces to mere 15% in the low-plateau AP clamp versus high-plateau
one (Appendix 1—figure 7), which is due to the slow time constant of activation
as described above. The fact that I  is capable of rapid activation (or recovery
from inactivation, mimicking activation) is independently corroborated also by
the elegant study of sinusoidal voltage pulse protocols by Beattie et al. (2018),
where I  responds noticeably to membrane potential changes around 0 mV.
Appendix 1—figure 7
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AP clamps and resulting I .
(A,B) Endocardial and Purkinje AP used as an AP clamp (5th beat of the simulation
shown). (C) I  produced by the endocardial AP. (D) I  produced by the Purkinje AP.
Shown are data manually … see more »
In addition to four drugs and their effect on APD reported in the main
manuscript Dutta et al. (2017b), also studied the effect of BaCl , modelled as a
90% IK  block. However, we excluded considering this drug fundamentally due
to the uncertainty on its multichannel effects on several potassium currents, in
addition to I . Specifically, it was previously shown that BaCl  also blocks I
and I  at the used concentration (Weerapura et al., 2004; Gibor et al., 2004).
Furthermore, as shown in Kristóf et al. (2012), even a lower dose of BaCl
prolongs the AP plateau and early phase of repolarization, thus at membrane
Kr
Kr Kr
13. Validation: drug block and APD
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potentials at which IK  is not activated. This corroborates that BaCl  is likely to
block I  and I , in addition to I , but to an uncertain degree. Furthermore,
pure block of I  in the ORd model results in APD prolongation from around −50
mV only, which indicates a clear discrepancy with the experimental data.
To further explore this issue, we simulated the effect of pure 90% I  block
(which is consistent with the concentration of BaCl  used in the experiments) as
well as additional I  block using the ToR-ORd. The results are shown in
Appendix 1—table 2.
Appendix 1—table 2
Effect of BaCl  on APD90 in experiments and simulations using the ToR-ORd model
with different degrees of I  and I  block.
For the three basic cycle length tested, the simulations are in overall agreement
with the experimental data (O'Hara et al., 2011), with an improved match for
90% I  + 15% I  block. It is however uncertain (albeit likely) whether the block
of other currents, such as for example I  contributes to explain the effect of
BaCl  on the APD.
A second matter discussed in this section is whether the assessment of
nisoldipine in Figure 5D classifies as a calibration or validation result. With
respect to I  block, the genetic algorithm optimisation contained a criterion
promoting APD shortening in response to a 50% calcium blockade; however, the
degree of block was different (90% when assessing nisoldipine), and the
optimiser did not aim specifically for the APD reported by Dutta et al. (2017a).
Additionally, the I  formulation substitution was motivated by the poor
performance of the original I  model in response to 50% I  blockade. After the
substitution was performed and the I  conductance scaled to achieve similar
APD at 1 Hz pacing at control conditions, no further optimization towards the
experimental data in Figure 5D was carried out. Specifically, at no time during
development was the model adjusted to provide predictions close to Dutta et al.
1 2
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2
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cycle
length
Experimental data
(O'Hara et al., 2011)
Simulated
90% I  block
Simulated 90% I  +
15% I  block
Simulated 90% I 1 +
30% I  block
500 ms 271 (±50) ms 250 ms 271 ms 297 ms
1000 ms 306 (±50) ms 281 ms 307 ms 341 ms
2000 ms 361 (±50) ms 286 ms 311 ms 342 ms
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(2017a) in reaction to 90% I . Therefore, APD shortening with I  blockade
could be considered a partially calibration criterion, but quantitatively a
validation one.
For extracellular potassium higher than 9 mM, a fibre was too inexcitable to
support the propagation of a full AP. However, a partial activation was observed
to propagate throughout the fibre, reaching ca. −30 mV and lasting ca. 50 ms
(Appendix 1—figure 8). In case of localised hyperkalemia, such as during acute
myocardial infarction, it is possible that even such low-peak wave might
reactivate nonischemic cells upon exit of the ischemic zone, triggering re-entry
and arrhythmia.
Appendix 1—figure 8
Subthreshold fibre activation under extreme hyperkalemia.
This trace was measured at the centre of the simulated fibre.
CaL CaL
14. Validation: propagation at extreme hyperkalemia
15.Simulation methods
15.1 Simulation details
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Cells were stimulated using a conservative potassium stimulus of −53 mV for 1
ms. Fixed concentrations in the model are: K  = 5 mM (extracellular potassium),
Na  = 140 mM (extracellular sodium), Ca  = 1.8 mM (extracellular calcium),
Cl  = 150 mM (extracellular chloride), Cl  = 24 mM (intracellular chloride).
All results are shown at the end of a 1000-beat long pre-pacing train of stimuli.
Fixed ionic concentrations were as stated above with two exceptions, where we
matched concentrations to the respective studies (this was done both for ToR-
ORd and ORd models when generating respective figures). The first exception is
the replication of the IV relationship and steady-state inactivation of I , based
on Magyar et al. (2000), where Na  = 140.7 mM, K  = 5.4 mM, Cl  = 146.2, and
Ca  = 2.5. Particularly, the calcium concentration is of importance, given that it
affects the driving force of calcium and thus the IV relationship directly. In
addition to the changed values of extracellular concentrations, we fixated the
intracellular concentrations of sodium (to 0 mM), potassium (to 153 mM), and
chloride (to 130 mM) to match concentrations in the patch-clamp pipette, given
that in the long-term, diffusion would distribute the ions in approximately such
way. We decided not to fix calcium levels in the model to the pipette
concentrations (which was calcium-free), given that calcium entry via I  and
the resulting release from the SR might last throughout the inactivating pulse,
affecting I  function in a persistent way.
A second exception is the protocol of induction of early afterdepolarisations
(EADs) based on Guo et al. (2011). In this case, Na  = 137, Cl  = 148, and Ca  = 2.
Third, for the P2/P1 protocol (Appendix 1-7), the concentrations were used as in
Fülöp et al. (2004): Cl  = 130 mM, Cl  = 157 mM, Na  = 144 mM, Ca  = 2.5 mM,
K  = 5.6 mM, K  = 153 mM, Na  = 0 mM.
Most of ionic remodelling was based on a comprehensive study by Coppini et al.
(2013). All remodelling of HCM cells versus healthy cells was preferentially
based on current density, protein expression if current density was not
available, or mRNA expression if neither of the previous two measurements was
available. The degree of remodelling was based on data means in the Coppini et
al. study; where two subunits of a complex underlying a current were altered,
an average of the two values corresponding to increase/reduction was used.
o
o o
o i
15.1.1 Single-cell simulation protocols
CaL
o o o
o
CaL
CaL
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15.1.2 Hypertrophic cardiomyopathy and hyperkalemia
representation
15.1.2.1 Hypertrophic cardiomyopathy
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Based on current density, I  was increased by 165%, I  by 25%, and I  was
reduced by 80%. In addition, consistent with the study, the time constant of fast
inactivation (both voltage and calcium-driven) was increased by 35%, and the
time constant of slow inactivation was increased by 20%. Based on protein
expression, NCX was increased by 50%, J  was reduced by 35%, and J  by 30%.
Based on mRNA, I  was reduced by 30%, I  by 35%, and I  by 55%. In addition,
I  was reduced by 30% (Passini et al., 2016), and calcium affinity of troponin
was increased slightly by reducing the K  by 7% (Robinson et al., 2007).
Extracellular potassium level was raised from 5 mM with an increment of 0.5
mM up to 10 mM. Effective refractory period was determined using S1-S2
protocol, recording the highest S2 coupling interval duration which did not lead
to propagation. Hyperkalemic conditions were simulated in a fibre, see below.
The 1D fibre tissue simulations (hyperkalemia and Appendix 1-11) were
conducted using the open-source software CHASTE. The homogeneous 1D tissue
fibres had a length of 4 cm consisting of 200 nodes, with a conductivity of 1.64
mS/cm to achieve a diffusion coefficient of 1.171 cm /s (Bueno-Orovio et al.,
2008). All the fibres were paced for 20 beats before analysis. For the purpose of
measurement of APD or effective refractory period, a stimulus was considered
‘propagating’ if the peak of membrane potential at the half-point of the fibre was
above 0. Stimuli which did not propagate did not have their APD or refractory
period measured.
To assess the performance of the newly developed model for studies of
populations of models, we constructed two populations of models using the ToR-
ORd model as baseline, and the experimentally-calibrated population of models
methodology (Britton et al., 2013; Muszkiewicz et al., 2016; Passini et al., 2017). A
total of nine ionic conductances were randomly varied: fast and late Na  current
(G  and G  respectively), transient outward K  current (G ), rapid and slow
delayed rectifier K  current (G  and G ), inward rectified K  current (G ), Na -
Ca2  exchanger (G ), Na -K  pump (G ) and the L-type Ca2  current (P ).
Two variability ranges were considered: [50-150]% and [0–200]% with respect to
the baseline values, consistent with the reference study (Passini et al., 2017). The
number of models passing calibration to experimental biomarkers was 2666 out
of 3000 models generated for the [50-150]% population, and 817 out of 3000 for
the [0–200]% population.
NaL CaL to
up rel
K1 Kr Ks
NaK
trp
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15.1.3 Fibre simulation
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To assess the suitability of the newly developed model for prediction of drug-
induced pro-arrhythmic risk, we also replicated the results of our previous study
on human in silico drug trials in population of human models (Passini et al.,
2017), by testing the same 62 reference compounds at multiple concentrations
on the [0–200%] population of models described above. Results were compared
in terms of occurrence of drug-induced repolarisation abnormalities (RA) in the
population and TdP score. CredibleMeds (Woosley and Romero, 2015) was used
as gold standard for TdP risk, dividing the reference compounds in four
categories: 1, high risk; 2, possible risk; 3, conditional risk; 4, safe (when not
included in CredibleMeds).
All the population of models described above were constructed using the Virtual
Assay software (v3.2.1119, 2019 Oxford University Innovation) (Passini et al.,
2017). Further analysis of the results was performed in Matlab (Mathworks Inc
Natwick, MA).
The formulation of transmurality (representation of endocardial,
midmyocardial, and epicardial cells) was retained as in O'Hara et al. (2011), with
two exceptions. First, the increase of I  conductance from endocardium to
midmyocardium was reduced to 2-fold, which corresponds to the mean of the
data (O'Hara et al., 2011, Figure 10). Second, the increase of I  from
endocardium to both midmyocardium and epicardium was reduced to 2-fold to
avoid excessive notch following the peak of the AP. Membrane potential traces of
the three cell types at 1 Hz pacing are given in Appendix 1—figure 9.
Appendix 1—figure 9
15.1.5 Transmurality, 3D simulation, and pseudo-ECG
measurement
CaL
to
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Action potential morphology for three cell subtypes at 1 Hz pacing.
The propagation of the electrical activity in the human ventricles was modelled
using the heart bidomain equations and solved with the Chaste software (Pitt-
Francis et al., 2009). A cardiac magnetic resonance (CMR)-informed torso
ventricular model was used. The ventricular element size was set to 0.4 mm to
ensure numerical convergence of the finite element software Chaste for
electrophysiological simulations (Dutta et al., 2016; Pitt-Francis et al., 2009).
The presented ToR-ORd model was used to represent the membrane kinetics.
Transmural and apex to base cell electrophysiological heterogeneities based on
experimental and clinical data from Okada et al. (2011); Drouin et al. (1995);
Taggart (2001); Boukens et al. (2015) were incorporated in the biventricular
heart model. Transmural heterogeneities were modelled using three layers as in
Lyon et al. (2018) of endocardial (45% of the transmural width), mid-myocardial
(25%) and epicardial cells (30%) with different AP properties as shown above.
Apex-to-base heterogeneities were modelled by including a gradual increase of
I  conductance from base to apex resulting in APD differences of 25 ms.
Heart fibre directions were generated using the Streeter rule-based method
(Streeter et al., 1969), and tissue conductivities were set to generate realistic
conduction velocities for the ToR-ORd cell model, numerical scheme, and mesh
resolution. The longitudinal intracellular conductivity of 1.64 mS/cm in a 1D
fibre model resulted in a physiological conduction velocity of ~65 cm/s (Taggart
Ks
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et al., 2000). As Cardone-Noott et al., 2016 used 1.5 mS/cm, intracellular
orthotropic conductivities and the axisymmetric extracellular conductivities
were obtained by using a scaling factor of 1.0934 to the ones in Cardone-Noott et
al., 2016.
Sinus rhythm was simulated at 1 Hz using a phenomenological activation model
with early endocardial activation sites and a fast endocardial layer representing
a tightly-packed endocardial Purkinje network (Cardone-Noott et al., 2016) and
adapted to the ventricular geometry (Mincholé et al., 2019).
Simulation of the pseudo-ECG was computed by calculating the extracellular
potentials in the virtual standard 12-lead electrode positions (Lyon et al., 2018)
from the ventricular geometry following the dipole model (Gima and Rudy,
2002) as:
where  are the electrode position coordinates,  is the diffusion
tensor, and  is the membrane potential. The integral is calculated over the
whole myocardium volume, .
We found it crucial to modify the behaviour of @ode15s in our simulations,
using Matlab ODE Events to limit 1 s of simulated time to 5 s of runtime (with the
runtime being <0.5 s in normal conditions), killing a simulation upon exceeding
the limit. When parameters of the models are randomly perturbed during GA
fitting, it is possible to achieve a combination which leads to model instability
and eventual crash. However, as ode15s attempts to reduce time step in such a
case, it takes up to 6 hr to crash, blocking CPU cores and stalling the whole
generation. With the timely killing of unstable simulations, we could run 30
generations with population size of 2500 in ca. 30 hr on an Azure virtual
machine with 64 cores, using parallel fitness evaluation.
In addition to the model code itself, we also provide a model evaluation pipeline.
This allows simulation of the single-cell calibration and validation criteria using
a standard model function (I.e. all except I  properties such as I-V relationship,
or disease models, where modified model codes are used.). After the simulation
of a comprehensive set of protocols, an HTML report is produced (Appendix 1—
figure 10), providing a clickable mapping between criteria and figures showing
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15.1.6 Timely killing of crashing simulations during
multiobjective GA
15.2 Evaluation pipeline and HTML reporter
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how the model fulfils them. Icons adjacent to the criteria allow rapid assessment
of whether the model behaves well in the given criterion. Any model with
appropriate interface of inputs and outputs can be simulated. It is particularly
easy to simulate variants of the ToR-ORd model, for example with changed
conductances of currents, as the same structure of parameters that is passed to
the model simulation wrapper can be passed to this evaluation pipeline. Given
that the evaluation code and subsequent report generation are fully automated,
it is easy to extend the pipeline to compute and visualise other evaluation
criteria.
Appendix 1—figure 10
Evaluation pipeline.
The left menu shows a list of evaluation criteria with the adjacent icon indicating
whether they are fulfilled by the model. The right pane contains figures visualising the
model performance in the … see more »
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The whole process of report generation (and storage of included plots) can be
run separately for calibration and validation criteria (with separately stored
figures), facilitating unbiased model development, where the model can be
assessed using the calibration criteria only, without the user observing any
validation results. It is nevertheless possible to also generate a report for only
validation criteria, or both calibration and validation.
Below are given the criteria evaluated, along with how the rating of the model is
defined (PASS = good behaviour in a given criterion, FAIL = problematic
behaviour, NA = feature not automatically compared to data, usually because of
difficulty of accurate rating; this code is also used when a plot is only an
illustration, such as examples of action potential shape at different pacing
frequencies). Unless specified otherwise, FAIL is given when PASS is not fulfilled.
1. Action potential morphology. PASS ~ AP from 10 to 500 ms is within the 10–
90% quantile range of the Szeged dataset. The first 10 ms are ignored so as not
to limit the model in its peak potential, as this is strongly modulated by cell
coupling (the available AP data are based on small-tissue samples).
2. Sample traces showing the AP and calcium transient at different pacing
frequencies. Always NA, this is just an illustrator figures useful for an
eyeballing-type of assessment.
3. Calcium transient properties (time to peak, duration at 90% recovery.
PASS ~ both features are within estimated standard deviation of data given in
Coppini et al. (2013).
4. Negative inotropy of 50% I  + 50% I  block. PASS if such treatment induces
a reduction in transient amplitude.
5. APD shortening with 50% I  block. PASS if such treatment induces APD
shortening.
6. The effect of 50% I  block on membrane potential. PASS if such treatment
induces depolarisation.
7. EAD formation. PASS if dV/dt exceeds 0.05 after 50 ms of the AP. This is
assessed at 4000 ms bcl, 85% I  block, and concentrations as given in section
1.3.1.
15.2.1 Calibration criteria
Na NaL
CaL
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8. Alternans formation. PASS if alternans of amplitude more than 5 ms is formed
at any frequency faster than 300 ms base cycle length. The plots generated
can be also used to assess dynamic restitution of APD.
Conduction velocity is not assessed, as it requires simulating a fibre using other
tools than Matlab.
1. Four simulated drug blocks from Dutta et al. (2017a):
E-4031 (I  blocker)
HMR-1556 (I  blocker)
Mexiletine (I , I , I  blocker)
Nisoldipine (I  blocker)
2. Each is simulated separately, and each is scored as PASS if the model
prediction is within the standard deviation of the data.
3. APD accommodation. Always NA, as it is challenging how to define agreement
with data exactly.
4. S1-S2 protocol. Always NA, just a comparison to data is given.
Effects of hyperkalemia, POM and drug safety testing, or 3D heart simulation are
not assessed automatically, as they requires simulation tools other than Matlab.
Below are the equations which have been added and/or changed in the ORd
model. The equations follow the naming convention of the ORd model with the
exception of I , I , I , and I , which are based on different models.
Membrane potential is expressed as .
The Grandi et al. (2010) model of I  was used as a baseline, which was extended
to account for the effect of CaMKII via modulation of the  gate (a shift by 6 mV)
and the 1.46 times increase of the time constant of  (recovery from
inactivation), consistent with (O'Hara et al., 2011). The current was included
15.2.2 Validation criteria
Kr
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15.3 Summary of updated equations
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within the membrane adjacent to the main cytosolic pool as in ORd. The
equations underlying describing the Grandi model were extracted from the
model source code.
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where  is the phosphorylated  gate,  is the phosphorylated  gate, and 
is the fraction of CaMKII-phosphorylated sodium channels.
As the ORd model assumes the time constant of I  activation to be the same as
the one of I ,  of I  in ToR-ORd was likewise set to  of the extended
Grandi I  model as described above.
In addition, the conductance was changed:
Steady-state activation was reformulated as the following Gompertz function
restricted to [0,1].
20% of I  was placed within the membrane adjacent to the main cytosolic ionic
pool ( ); 80% is included within membrane adjacent to the 'subspace'
compartment ( ). Total I  (the sodium and potassium currents carried by
the channel are treated analogously) is given as follows:
The two parts of I  differ in the driving force (which differs between subspace
and main ionic pool based on potentially different ionic concentrations), and ,
the variable determining the degree of calcium inactivation. We separated the
=
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original  variable into  (fraction of calcium-inactivated I  channels in the
junctional subspace) and  (fraction of calcium-inactivated I  channels in the
main cytosolic ionic pool). These are updated as  in the original model, except
that  is updated using the calcium concentration in the main cytosolic pool,
rather than in junctional subspace.
Driving force is modelled using the Goldman-Hodgkin-Katz equation as in the
original model, but this is computed separately for I  adjacent to junctional
subspace compartment and the main cytosolic ionic pool, using corresponding
ionic concentrations and activity coefficients. Activity coefficient  (activity
of ionic specie X, such as Ca, Na, or K in the junctional subspace compartment) is
computed dynamically based on Davies equation:
where ,  is the charge of X, and  is the ionic
strength:
where  is the molarity (I.e. the concentrations used throughout the model,
which are given in mM, are divided by 1000 to convert them to M.) of the i-th ion
(ToR-ORd takes into account calcium, sodium, potassium, and chloride) in the
given compartment, and  is its charge.
In total, three values of ionic strength are used in ToR-ORd for one ionic specie,
one for each of the following compartments: extracellular, main intracellular
pool, and junctional subspace. This then yields three corresponding activity
coefficients for the given ionic specie.
n n
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The Lu-Vandenberg (Lu et al., 2001) model was used, with structure given in
Figure 1B of the main manuscript. The model is used as published, except with
slightly increased , and different conductance. In this section,  without a
subscript stands for the fraction of channels in the inactivated state, not for a
current.
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 stands for extracellular potassium concentration.
The formulation below is based on Carro et al. (2011), updated to take into
account that extracellular potassium in our model is 5 mM, rather than 5.4.
Fraction of NCX in the junctional subspace was set to 0.35.
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This current is placed within the junctional subspace
The second half of the right hand side (from  on, inclusive) is the Goldman-
Hodgkin-Katz driving force;  is the activity coefficient of intracellular
calcium (in the main ionic pool), and  is the activity coefficient of
extracellular calcium.
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Acceptance summary:
This work constitutes a significant advancement in the field of theoretical
cardiac electrophysiology. Not only is the proposed mathematical model of the
human ventricular myocyte an improvement over existing models, in terms of
its correspondence with experimental data and its potential to accelerate
therapeutic developments in human cardiac electrophysiology; in addition, the
calibration and validation of this model also exemplifies a rigorous methodology
that will hopefully become standard in this field.
Decision letter after peer review:
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of a novel human ventricular myocyte model in health, disease, and drug block"
for consideration by eLife. Your article has been reviewed by three peer
reviewers, and the evaluation has been overseen by José D. Faraldo-Gómez as
Reviewing Editor and Naama Barkai as the Senior Editor. The following
individuals involved in the review of your submission have agreed to reveal
their identity: Thomas Hund (Reviewer #1); Molly Maleckar (Reviewer #3).
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Although it is customary for eLife to condense reviewers' reports into a concise
decision letter, in this case the Reviewing Editor believes it would be best to
enclose these reports as originally submitted. Based on these reports, we would
like to invite you to submit a revised version of your manuscript that addresses
the questions and concerns raised.
Reviewer #1:
This paper presents a modified model of the human ventricular action potential
based on a published model from the Rudy group (O'hara Rudy – ORd model).
Changes were made to improve the ability of the model to reproduce different
aspects of the action potential – especially the plateau potential and APD
accommodation. To achieve this goal, Tomek et al. modified the L-Type calcium
channel, as well as replacing the formulation of the sodium channel and rapid
delayed rectifier channel. The L-Type channel was modified by re-deriving the
ionic activity, and treating it as variable in subspaces and time. The L-Type was
then also refit using the activation curve normalized to the GHK driving force,
rather than the Nerst driving force as was done previously. Additionally, the
formulation of the sodium channel was replaced with a version from Grandi et
al., 2010, and I  was replaced with a version from Lu et al., 2001. The changes
were than fit to data from the original O'Hara Rudy paper and elsewhere.
Finally, the model was validated against APD accommodation from O'Hara, 2011,
drug safety predictions, and more, including ECG results from whole heart
simulations. This model introduces several notable improvements to the O'Hara
Rudy model that will be of interest to mathematical modeling researchers.
1) Chloride current is added to the model without fitting or showing how it
affects the model. Additionally, it would be helpful to have a justification of why
these currents were added, as well as validated.
2) In Figure 2, inclusion of the other main dataset used by O'Hara to fit the L-
Type channel would help in the comparison of the new L-Type formulation to
the old formulation. (Fulop et al., 2004).
3) In Figure 5, the fit of the fifth drug, BaCl , would still be interesting to see as it
was used in both O'Hara and Dutta et al., 2017, despite BaCl  having off-target
effects.
4) Please review all equations for typos.
Reviewer #2:
Kr
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Tomek et al. have put a tremendous amount of effort into improving the O'Hara
et al. mathematical model of the human ventricular myocyte. The
correspondence of the new model with experimental data is quite impressive,
and the authors have done a laudable job of separating the calibration and
validation steps in model development. Because these steps have often been
combined and/or blurred in previous work in this field, the study provides
additional rigor by separating the two steps. Moreover, given the central
importance of the O'Hara et al. model in the field, there is a need for
improvements, and this work most likely represents a major step in the right
direction. These are all reasons to like the paper.
All of that being said, there are certain aspects of the manuscript that are rather
confusing and need to be improved. Although the comments below may seem
excessive to the authors, it did in fact take multiple readings and considerable
additional thinking for this reviewer to fully comprehend some of what the
authors had done. It can be a difficult goal to achieve, but the authors should
aim for a paper that can be readily understood, even by non-experts, after a
single reading. The manuscript doesn't meet that standard at present.
1) One of the most interesting aspects of the manuscript is the discussion of
activity coefficients, I  current-voltage plots, and the extraction of activation
curves (subsection “In-depth revision of the L-type calcium current”). The
reviewer absolutely concurs that because many formulations have been
inherited from previous models, often without rigorous examination of these
formulations, it is entirely appropriate to examine these assumptions and re-
formulate currents if necessary. However, this discussion is ultimately
unconvincing, and the presentation needs to be modified for this section to be
fully understood.
1a) The discussion of the activity coefficients is interesting and will be
informative to readers unfamiliar with this primary literature. However,
although the authors make a compelling case that different activity coefficients,
i.e. closer to 0.6, should be used, the manuscript leaves out the most important
question, namely: how do these changes affect the I-V curves?
1b) Speaking of I-V curves, examination of Figure 1D makes a convincing case
that the new model has a different shape and matches the experimental data
better. However, it's not clear why this occurs – what allows this better fit? Is this
due to the changes in activity coefficients? Is it just from the better activation
curve shown in Figure 1C? Another fact that can affect this curve is the relative
permeability of the channel to Na and K compared with Ca. It's odd that this is
never addressed in the manuscript. Did the authors modify this to try to fit the
curves better, or were these numbers considered fixed based on original data?
CaL
This site uses cookies to deliver its services and analyse traffic. By using this site, you agree to its use of
cookies. Learn more.
GOT IT
2020. 09. 11. Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block | eLife
https://elifesciences.org/articles/48890#info 79/101
1c) The term "driving force" is used in the manuscript in a way that is
inconsistent with prior literature. One of the appeals of Ohmic formulations is
that driving force is expressed in units of volts, and conductance can be derived
from current plots by simple division. But with a GHK formulation, things are
not so simple. The term called "driving force" here does not appear to be in units
of volts, so what exactly is this term representing?
1d) Finally, on this same topic, the Discussion states: "Activation curve of the
current in previous cardiac models was based on the use of Nernst driving force
in experimental studies, but the models then used Goldman-Hodgkin-Katz
driving force to compute the current." Again, it's not completely clear how the
authors derive one set of numbers (i.e. activation at defined voltages) from a
different set of numbers (i.e. current at those same voltages). As I have been
writing this, it has occurred to me that perhaps the units of driving force are less
relevant, as long as one set of numbers can be multiplied by a different set of
numbers to ultimately produce current. However, the fact that I've had to think
so hard about this demonstrates that the manuscript needs to do better. Because
the I  formulation is claimed in the Discussion as "the greatest theoretical
contribution of this work," the explanations here need to be crystal clear.
Perhaps the supplement should contain flow charts of the conventional method
for extracting I  activation versus how the new approach improves this, as
well as plots showing how the changes to the activity coefficients influence the
IV curves.
2) The discussion of Na current blockade and inotropy is relatively weak.
Perhaps the authors need to reproduce some original experimental data, or, at
the very least, provide some numbers extracted from the earlier studies. The
description of Figure 3 discusses the "negative inotropy" previously reported
with Na channel blockers, but with no numbers provided. The change in Ca
transient amplitude shown in Figure 3C is very small, probably undetectable
experimentally. If experiments have reported a 50% decrease in contraction
strength, I would say that neither model is consistent, although ToR-ORd is
slightly better. Obviously the heatmaps in 3E and 3F provide additional
information, but in general here the correspondence with data can be discussed
in a more quantitative way. In the Discussion, the phrase "good response of the
ToR-ORd model to sodium blockade" sticks out as rather vague.
2a) Again on the Na channel block-inotropy issue. The authors have an
opportunity to obtain new mechanistic insight here given that the response of
the two models is different. My suspicion is that it might have less to do with the
AP morphology, as speculated in the Discussion, and more to do with
intracellular [Na] regulation. However, since mechanisms are not explored, we
don't know which idea is correct. It might be considered beyond the scope of this
CaL
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study to obtain this mechanistic insight, but it's an interesting question, and the
new model provides a means for addressing it.
3) The description of hyperkalemia simulation in Figure 8 should be improved.
First, the text claims that Figure 8A shows a "progressive" increase in resting
potential and slowing of upstroke velocity. But since the figure only shows 2
examples, it's hard to see that this is progressive. Second, PRR is used in this
description but has not been previously defined. It took a few seconds to figure
out what the authors meant. Is it really necessary to have an abbreviation for a
term that's only used once in the manuscript?
4) The last paragraph of the Discussion, discussing future directions, should be
modified. This paragraph states: "Similarly to most existing cardiac models, the
equations governing the release depend directly on the L-type calcium current,
rather than on the calcium concentration adjacent to the ryanodine receptors,
which is the case in cardiomyocytes. Future development of the ryanodine
receptor model and calcium handling will extend the applicability of the
model.…"
The first sentence is correct, the second is not. The challenge is not to improve
the representation of the ryanodine receptor. This will not fix the problems; the
problems arise from the fact that Ca release in cells is controlled locally rather
than globally – this is why whole cell models, that use a single variable to
describe ryanodine receptor gating, need to use shortcuts such as making
release directly dependent on I . This general problem was rigorously
analyzed by Stern way back in 1992 (PMID: 1330031). For more discussion, see
also PMIDs: 15465866, 20346962, 21586292.
It's great to discuss potential future improvements to the EC coupling part of the
model, but these discussions should acknowledge that the issue is not just
improving the RyR model, but that stochastic triggering of locally-controlled Ca
sparks will need to be described.
Reviewer #3:
Mature models and simulation techniques in human cardiac electrophysiology
can now be exploited to accelerate therapeutic development and validation e.g.
devices, drug development/cardiotoxicity. The authors identify key weaknesses
in a model of the human ventricular action potential (ORd, which has been
chosen previously by an expert-led initiative to represent the human ventricular
AP in validation studies incorporating models and simulation), and present an
updated (novel) model of the human AP, the ToR-ORd, to address these.
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Overall, the work addresses an important need: in order to effectively translate
value from models and simulations in the hoped-for context of human
ventricular electrophysiology, the primary model's weaknesses must absolutely
be addressed for utility, and so I would consider this work far beyond
incremental and a very useful contribution in terms of model to the field at this
juncture. The work also nicely leverages a plethora of prior experimental work
using direct electrophysiological measurements for calibration and validation.
In general, the work is very well organized and well-written.
Comments:
- Cogent, well-motivated Introduction. Weaknesses of ORd (AP plateau potential,
APD adaptation and response to sodium current block) and solutions (L-type
calcium, excitation contraction coupling and hERG current re-assessment and
reformulations) clear.
- Overall goal to design, develop, calibrate and validate the novel ToR-ORd
model, with aim of reproducing all key depolarization, repolarization and
calcium dynamics properties in healthy human ventricular cells and when these
are under drug block, as well as in diseased conditions e.g. hyperkalemia and
hypertrophic cardiomyopathy is both timely and useful.
- Importantly, calibration and validation processes are independent, using
independent datasets
- "The I  current was deeply revisited, particularly with respect to its driving
force, based on biophysical principles." – well-motivated, needed, seldom done,
valuable to other models. "This allows accurate representation of the driving
force when ionic concentrations are disturbed,"
- Really encouraging to see disease-based, multi-scale validation of this nature.
Impact for translational work made abundantly clear.
Concerns/areas to address:
1) Given the journal's wide appeal, there is a need to better introduce the
strategy and process going into the Materials and methods section, from "We
initially performed the evaluation of the ORd model (O'Hara et al., 2011) against
calibration criteria…". While I appreciated the simplicity of explanation in
general, this guiding summary can be improved to clarify what was initially
done and why and how the strategy developed
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2) It's also not immediately clear what the calibration criteria actually are (Table
1) – I assume that, in addition to the listed references, that these exist in a
supplement somewhere and it would be great to point the reader to this
3) "Simulations with the existing versions of the ORd model failed to fulfil key
criteria such as AP morphology, calcium transient duration, several properties of
the L-type calcium current, negative inotropic effect of sodium blockers, or the
depolarising effect of I  block" – where is this shown? Is there a supplementary
figure?
4) In-depth revisions based on fundamental physical principles is a much-
needed process. Some motivation and/or discussion of the state of the art in this
particular field (i.e. how some attention to the underlying biophysics was laid by
the wayside in model redevelopment, experimental assimilation, and
subsequent versioning, and conjectures as to why e.g. computational tools like
versioning tools did not exist, would be appropriate
5) Given the progressive, savvy lean of this work, it seems reasonable to ask why
authors did not consider making the code available in other formats, e.g. python
as well, or at least justify/mention the relevance of language and tools for
reuse/reproducibility/versioning. Similarly, reference to other recent forays into
systematic model improvement, e.g. functional curation and web lab, seems
warranted
6) Results: "This [ToR-ORd model yields negative I  values in such conditions]
is a direct consequence of the updates to the extracellular/intracellular calcium
activity coefficients, which supports its credibility and it is important for cases of
elevated I , such as under ß-adrenergic stimulation." – while this is likely true,
it also seems likely a throwaway – were any simulations run using the model to
demonstrate the importance in this vein? Important how?
7) Results/Figure 3: Besides noting that the ToR-ORd is consistent with observed
negative inotropy of sodium blockers, it is unclear from text how updated model
compares in terms of available experimental data, i.e. "A mild increase in
inotropy may be achieved only under near-exclusive I  block." – or whether
this comparison is available at all.
8) Figure 5A, B, C – the slope of the APD90 dependence on BCL for the ToR-ORd
differs consistently from that of the data for BCLs > 1s – any musings as to
mechanism? Either briefly in main text or supplement.
9) Figure 6C: would strengthen the case for the ToR-ORd further to compare
restitution for ORd in a fibre under same protocol?
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10) Seems like suitability of ToR-ORd for drug safety testing is clear – and
discussion around this is adequate and encouraging. However, there still does
not seem to be a marked improvement in the example given over the ORd
(Figure 7), particularly in terms of false negatives. Authors note "further
improvement to the score is likely with development of a population optimised
towards drug safety assessment" – so it will be interesting to see results there.
https://doi.org/10.7554/eLife.48890.sa1
Reviewer #1:
1) Chloride current is added to the model without fitting or showing how it
affects the model. Additionally, it would be helpful to have a justification of why
these currents were added, as well as validated.
The chloride currents were parametrised exactly as in Grandi et al., 2010, (only
the conductances were adjusted). We have now added a more detailed
description of their effect and justification in the Materials and methods.
“The motivation to add these currents was to facilitate the shaping of post-peak
AP morphology (via I ), with I  playing a dual role stemming from its
reversal potential of ca. -50 mV. It slightly reduces plateau potentials during the
action potential, but during the diastole, it depolarises the cell slightly,
improving the reaction to I  block as explained in the next subsection.”
2) In Figure 2, inclusion of the other main dataset used by O'Hara to fit the L-
Type channel would help in the comparison of the new L-Type formulation to
the old formulation. (Fulop et al., 2004).
Thank you for the comment. We have now simulated this protocol and added it
as Appendix 1—figure 4, with a mention in the main manuscript. Simulated data
with the ToR-ORd are similar to the experimental recordings and the ones
obtained with the ORd in that a) the short pulse-curve lies above the long-pulse
curve, b) the shorter coupling interval is associated with less current availability.
Both models yield an offset with respect to the experimental data. This could be
due to a) Difference in I  behaviour/density and/or calcium loading (affecting
inactivation) between the Fülöp (P2/P1 protocol) and Magyar (the main basis for
the I  model) studies i.e., it is possible that even the living cells could manifest
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different properties. It could be also linked to mechanisms of I  inactivation
not represented in the model (e.g. the inactivation by the calcium flow through
the channel, represented e.g., by Mahajan et al., 2008). If we accelerate I
inactivation, we observed that the model stopped being capable of manifesting
EADs, which is a very important feature, and losing it would make the model
less useful than in the current form. We speculate that a more complex model
structure as well as calcium-sensitive SR release may be required to achieve a
model with sufficiently fast inactivation, but which is nevertheless capable of
manifesting EADs. This is future work that we will most likely work on in the
future, but it is currently well beyond the scope of this paper.
3) In Figure 5, the fit of the fifth drug, BaCl , would still be interesting to see as it
was used in both O'Hara and Dutta et al., 2017, despite BaCl  having off-target
effects.
Thank you for this comment. We have now included an explanation in the
manuscript as to why we chose not to include a comparison to BaCl  (Main text
subsection “Validation: Drug-induced effects on rate dependence of APD” and
Appendix 1 subsection “Validation: Drug block and APD”). This is fundamentally
due to the uncertainty concerning its multichannel effects on several potassium
currents, in addition to I . It was previously shown that BaCl  blocks also I
and I  at the used concentration (Weerapura et al., 2000; Gibor et al., 2004).
Furthermore, as shown in (DOI 10.1371/journal.pone.0053255), even a lower
dose of BaCl  prolongs the AP plateau and early phase of repolarization, thus at
membrane potentials at which I  is not activated. This supports the supposition
that BaCl  is likely to block I  and I , in addition to I , but to an uncertain
degree. Furthermore, pure block of I  in the ORd model results in APD
prolongation from around -50mV only, which indicates a clear discrepancy with
the experimental data.
4) Please review all equations for typos.
Thank you, we have double-checked the equations.
Reviewer #2:
[…] All of that being said, there are certain aspects of the manuscript that are
rather confusing and need to be improved. Although the comments below may
seem excessive to the authors, it did in fact take multiple readings and
considerable additional thinking for this reviewer to fully comprehend some of
what the authors had done. It can be a difficult goal to achieve, but the authors
should aim for a paper that can be readily understood, even by non-experts,
after a single reading. The manuscript doesn't meet that standard at present.
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1) One of the most interesting aspects of the manuscript is the discussion of
activity coefficients, I  current-voltage plots, and the extraction of activation
curves (subsection “In-depth revision of the L-type calcium current”). The
reviewer absolutely concurs that because many formulations have been
inherited from previous models, often without rigorous examination of these
formulations, it is entirely appropriate to examine these assumptions and re-
formulate currents if necessary. However, this discussion is ultimately
unconvincing, and the presentation needs to be modified for this section to be
fully understood.
Thank you for highlighting the importance of this point. Following the
reviewer’s suggestions, we have substantially expanded the description of the
implications of the reformulation of the I  properties, with new results and
discussion. This is explained in more detailed in the following sub-points.
1a) The discussion of the activity coefficients is interesting and will be
informative to readers unfamiliar with this primary literature. However,
although the authors make a compelling case that different activity coefficients,
i.e. closer to 0.6, should be used, the manuscript leaves out the most important
question, namely: how do these changes affect the I-V curves?
Thanks for the comment. We have now introduced/expanded sections in
Appendix 1, subsections “I  updates and the I-V relationship”, “I  reversal
and ionic activity coefficients” and “Role of I  properties and AP morphology
in calcium transient changes by sodium blockade” to explain the effect of the
revision of the activity coefficients more clearly. The shape of the I-V
relationship is affected predominantly by the update of the activation curve as
shown in Appendix 1—figure 2. This supports the case that the activation curve
needs to be extracted by considering the Goldman-Hodgkin-Katz (GHK) driving
force in models which use the GHK equation to compute the L-type calcium
current (as explained in the Materials and methods subsection “Activation curve
extraction”).
The activity coefficients themselves have an important contribution in the
improved response to sodium block (Appendix 1 subsection “Role of I
properties and AP morphology in calcium transient changes by sodium
blockade”) and also in avoiding the reversal of the I  to outward current
(Figure 2F), which is exhibited by the ORd model, (Appendix 1—figure 6).
1b) Speaking of I-V curves, examination of Figure 1D makes a convincing case
that the new model has a different shape and matches the experimental data
better. However, it's not clear why this occurs – what allows this better fit? Is this
due to the changes in activity coefficients? Is it just from the better activation
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curve shown in Figure 1C? Another fact that can affect this curve is the relative
permeability of the channel to Na and K compared with Ca. It's odd that this is
never addressed in the manuscript. Did the authors modify this to try to fit the
curves better, or were these numbers considered fixed based on original data?
As mentioned in the previous comment, we have now dissected the role of
activation curve versus activity coefficients in Appendix 1, subsections “I
updates and the I-V relationship”, “I  reversal and ionic activity coefficients”
and “Role of I  properties and AP morphology in calcium transient changes by
sodium blockade”. The relative permeability to Na and K was kept as in the
original ORd model; their ratio to Ca permeability was kept constant, given that
the data were not challenged by new evidence.
1c) The term "driving force" is used in the manuscript in a way that is
inconsistent with prior literature. One of the appeals of Ohmic formulations is
that driving force is expressed in units of volts, and conductance can be derived
from current plots by simple division. But with a GHK formulation, things are
not so simple. The term called "driving force" here does not appear to be in units
of volts, so what exactly is this term representing?
This is addressed together with the following comment.
1d) Finally, on this same topic, the Discussion states: "Activation curve of the
current in previous cardiac models was based on the use of Nernst driving force
in experimental studies, but the models then used Goldman-Hodgkin-Katz
driving force to compute the current." Again, it's not completely clear how the
authors derive one set of numbers (i.e. activation at defined voltages) from a
different set of numbers (i.e. current at those same voltages). As I have been
writing this, it has occurred to me that perhaps the units of driving force are less
relevant, as long as one set of numbers can be multiplied by a different set of
numbers to ultimately produce current. However, the fact that I've had to think
so hard about this demonstrates that the manuscript needs to do better. Because
the I  formulation is claimed in the Discussion as "the greatest theoretical
contribution of this work," the explanations here need to be crystal clear.
Perhaps the supplement should contain flow charts of the conventional method
for extracting I  activation versus how the new approach improves this, as
well as plots showing how the changes to the activity coefficients influence the
IV curves.
Thank you for this suggestion. We have addressed this issue by adding a block of
text at the start of the Materials and methods subsection “In-depth revision of
the L-type calcium current”which clarifies the term “driving force” in the
manuscript (a number that multiplies conductance/permeability and gating
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variables to produce total current). In addition, we have included a diagram and
explanation in Appendix 1—figure 3 illustrating the extraction of activation
curve. Together with the newly added Appendix subsections “ICaL updates and
the I-V relationship”, “ICaL reversal and ionic activity coefficients” and “Role of
ICaL properties and AP morphology in calcium transient changes by sodium
blockade”, the manuscript now gives quantitative insight into the effects of the
updates to I  introduced in our work.
2) The discussion of Na current blockade and inotropy is relatively weak.
Perhaps the authors need to reproduce some original experimental data, or, at
the very least, provide some numbers extracted from the earlier studies. The
description of Figure 3 discusses the "negative inotropy" previously reported
with Na channel blockers, but with no numbers provided. The change in Ca
transient amplitude shown in Figure 3C is very small, probably undetectable
experimentally. If experiments have reported a 50% decrease in contraction
strength, I would say that neither model is consistent, although ToR-ORd is
slightly better. Obviously the heatmaps in 3E and 3F provide additional
information, but in general here the correspondence with data can be discussed
in a more quantitative way. In the Discussion, the phrase "good response of the
ToR-ORd model to sodium blockade" sticks out as rather vague.
We have now added a more detailed comparison to available clinical data in the
manuscript, subsection “Calibration: Inotropic effects of sodium blockers”).
The 15% reduction in CaT amplitude observed with sodium block in fibre
simulations with the ToR-ORd model (Appendix 1 subsection “Summary of
literature on sodium blockers, I , and I  reduction”) is consistent with
experimental measurements (showing changes of 9-28%, depending on the
study and index of contractility). A quantitative comparison is challenging given
the different measures of inotropic properties. Furthermore, the degree of I
and I  block is estimated rather than known with precision, as also discussed
in Appendix 1. Thus, the drugs studied may block I  and I  in a different ratio
than 50:50 (suggesting I  block may be stronger than I  block; Appendix 1,
subsection “Role of I  properties and AP morphology in calcium transient
changes by sodium blockade”), potentially also altering the CaT amplitude
reduction in simulations.
2a) Again on the Na channel block-inotropy issue. The authors have an
opportunity to obtain new mechanistic insight here given that the response of
the two models is different. My suspicion is that it might have less to do with the
AP morphology, as speculated in the Discussion, and more to do with
intracellular [Na] regulation. However, since mechanisms are not explored, we
don't know which idea is correct. It might be considered beyond the scope of this
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study to obtain this mechanistic insight, but it's an interesting question, and the
new model provides a means for addressing it.
We have now offered mechanistic insight into this issue in Appendix 1,
subsection “Calibration: I  block and I  replacement”. We provide the results
of additional simulations using AP clamping and selective addition of I
updates to dissect how the different updates contribute to the sodium block
simulation results. The data demonstrate the importance of AP morphology, as
shown in Appendix—table 1, and also Appendix 1—figure 7. We agree with the
reviewer that further investigations into sodium regulation could be the focus of
future studies.
3) The description of hyperkalemia simulation in Figure 8 should be improved.
First, the text claims that Figure 8A shows a "progressive" increase in resting
potential and slowing of upstroke velocity. But since the figure only shows 2
examples, it's hard to see that this is progressive. Second, PRR is used in this
description but has not been previously defined. It took a few seconds to figure
out what the authors meant. Is it really necessary to have an abbreviation for a
term that's only used once in the manuscript?
Thank you for bringing this to our attention; we rewrote PRR as
postrepolarization refractoriness, and we removed the “progressive”.
4) The last paragraph of the Discussion, discussing future directions, should be
modified. This paragraph states: "Similarly to most existing cardiac models, the
equations governing the release depend directly on the L-type calcium current,
rather than on the calcium concentration adjacent to the ryanodine receptors,
which is the case in cardiomyocytes. Future development of the ryanodine
receptor model and calcium handling will extend the applicability of the
model.…"
The first sentence is correct, the second is not. The challenge is not to improve
the representation of the ryanodine receptor. This will not fix the problems; the
problems arise from the fact that Ca release in cells is controlled locally rather
than globally – this is why whole cell models, that use a single variable to
describe ryanodine receptor gating, need to use shortcuts such as making
release directly dependent on I . This general problem was rigorously
analyzed by Stern way back in 1992 (PMID: 1330031). For more discussion, see
also PMIDs: 15465866, 20346962, 21586292.
It's great to discuss potential future improvements to the EC coupling part of the
model, but these discussions should acknowledge that the issue is not just
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improving the RyR model, but that stochastic triggering of locally-controlled Ca
sparks will need to be described.
Thank you for the comment. We have now rephrased this part of Discussion,
acknowledging more possible future directions in line with the reviewer’s
suggestions.
Reviewer #3:
Comments:
- Cogent, well-motivated Introduction. Weaknesses of ORd (AP plateau potential,
APD adaptation and response to sodium current block) and solutions (L-type
calcium, excitation contraction coupling and hERG current re-assessment and
reformulations) clear.
- Overall goal to design, develop, calibrate and validate the novel ToR-ORd
model, with aim of reproducing all key depolarization, repolarization and
calcium dynamics properties in healthy human ventricular cells and when these
are under drug block, as well as in diseased conditions e.g. hyperkalemia and
hypertrophic cardiomyopathy is both timely and useful.
- Importantly, calibration and validation processes are independent, using
independent datasets
- "The ICaL current was deeply revisited, particularly with respect to its driving
force, based on biophysical principles." – well-motivated, needed, seldom done,
valuable to other models. "This allows accurate representation of the driving
force when ionic concentrations are disturbed,"
- Really encouraging to see disease-based, multi-scale validation of this nature.
Impact for translational work made abundantly clear.
Concerns/areas to address:
1) Given the journal's wide appeal, there is a need to better introduce the
strategy and process going into the Materials and methods section, from "We
initially performed the evaluation of the ORd model (O'Hara et al., 2011) against
calibration criteria…". While I appreciated the simplicity of explanation in
general, this guiding summary can be improved to clarify what was initially
done and why and how the strategy developed.
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Thank you for this comment. We have now provided further clarifications in the
section.
2) It's also not immediately clear what the calibration criteria actually are (Table
1) – I assume that, in addition to the listed references, that these exist in a
supplement somewhere and it would be great to point the reader to this.
We have added a new section Appendix 1 subsection “Calibration criteria”
which concretely discusses the calibration criteria in greater detail.
3) "Simulations with the existing versions of the ORd model failed to fulfil key
criteria such as AP morphology, calcium transient duration, several properties of
the L-type calcium current, negative inotropic effect of sodium blockers, or the
depolarising effect of I  block" – where is this shown? Is there a supplementary
figure?
We have now clarified where the results are shown:
“Simulations with the existing versions of the ORd model failed to fulfil key
criteria such as AP morphology, calcium transient duration, several properties of
the L-type calcium current, negative inotropic effect of sodium blockers, or the
depolarising effect of I  block” (later shown in Figures 2, 3, and Materials and
methods subsection “Calibration of I  block and resting membrane potential”).
4) In-depth revisions based on fundamental physical principles is a much-
needed process. Some motivation and/or discussion of the state of the art in this
particular field (i.e. how some attention to the underlying biophysics was laid by
the wayside in model redevelopment, experimental assimilation, and
subsequent versioning, and conjectures as to why e.g. computational tools like
versioning tools did not exist, would be appropriate.
Our approach of clear calibration criteria and using the genetic algorithm for
parameter fitting was very helpful in identifying properties that needed revising
from fundamental physical principles. This allowed to effectively identify first
the I  properties and then the I  structure as the two critical aspects that
required in depth revisiting, based also on AP morphology. It was very useful to
be able to test the effect of different I  model structures, which needed manual
coding from the papers. Initiatives such as cellML make this process more
efficient, and this is why we share our code in such format. Also to facilitate
versioning of this model, we are posting on github. We have now specified these
points both in Materials and methods and Discussion.
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5) Given the progressive, savvy lean of this work, it seems reasonable to ask why
authors did not consider making the code available in other formats, e.g. python
as well, or at least justify/mention the relevance of language and tools for
reuse/reproducibility/versioning. Similarly, reference to other recent forays into
systematic model improvement, e.g. functional curation and web lab, seems
warranted.
Matlab was chosen as it’s one of the most widely used tools for cardiac
simulations. Our practical experience is that it is very convenient tool for model
development, given the way in which it integrates capabilities of simulation,
visualisation, analysis, and introspection (via debugger which is an excellent
tool to get insight into why the model behaves in a particular way).
CellML was chosen as the leading standard of model formulations, and as it can
be used in simulators such as Chaste or OpenCOR, and as it may be imported
into other platforms including the Myokit library which can convert CellML to
Python or C, making it a very flexible format. Furthermore, we also provide an
evaluation pipeline to facilitate model validation and future work. We extended
the Materials and methods subsection “Evaluation pipeline and code” to
explicitly point the reader to all these options, which we trust will facilitate the
uptake of the model.
6) Results: "This [ToR-ORd model yields negative I  values in such conditions]
is a direct consequence of the updates to the extracellular/intracellular calcium
activity coefficients, which supports its credibility and it is important for cases of
elevated I , such as under ß-adrenergic stimulation." – while this is likely true,
it also seems likely a throwaway – were any simulations run using the model to
demonstrate the importance in this vein? Important how?
Many thanks for raising this important question. We have now added Appendix
1, subsection “I  reversal and ionic activity coefficients”, explaining this in
greater detail, demonstrating the difference the updated activity coefficients
make in the GHK equation.
7) Results/Figure 3: Besides noting that the ToR-ORd is consistent with observed
negative inotropy of sodium blockers, it is unclear from text how updated model
compares in terms of available experimental data, i.e. "A mild increase in
inotropy may be achieved only under near-exclusive I  block." – or whether
this comparison is available at all.
We agree this is very important and we’ve added a paragraph at the end of
Results subsection “Calibration: Inotropic effects of sodium blockers”.
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8) Figure 5A, B, C – the slope of the APD90 dependence on BCL for the ToR-ORd
differs consistently from that of the data for BCLs > 1s – any musings as to
mechanism? Either briefly in main text or supplement.
Our results show that the simulated data are overall within the experimental
range. There is indeed a slight difference in the slope of the APD90 dependence
for long BCL between the simulated data and the mean experimental recordings.
The mean experimental data for each BCL are an average of many traces, some
of which may be consistent with the simulation shown. In a population-of-
models approach, it is likely that there will be, in turn, models highly consistent
with the data means.
9) Figure 6C: would strengthen the case for the ToR-ORd further to compare
restitution for ORd in a fibre under same protocol?
Thank you. We have added this to the figure.
10) Seems like suitability of ToR-ORd for drug safety testing is clear – and
discussion around this is adequate and encouraging. However, there still does
not seem to be a marked improvement in the example given over the ORd
(Figure 7), particularly in terms of false negatives. Authors note "further
improvement to the score is likely with development of a population optimised
towards drug safety assessment" – so it will be interesting to see results there.
Thank you. The aim of this section of the Results was to show that the accuracy
for drug-induced pro-arrhythmic risk was also high and similar to the one with
the ORd. We have deleted this sentence to avoid confusion as further
development to improve the accuracy, which is already high, would be beyond
the scope of this work.
https://doi.org/10.7554/eLife.48890.sa2
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